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Preeclampsia (PE) is a disease of late pregnancy characterized by maternal hypertension
and proteinuria. It is associated with preterm delivery and significant perinatal morbidity and
mortality. Despite affecting ~7% of first pregnancies, there is no effective screening method to
identify women at risk, nor is there a definitive treatment other than delivery of the baby and
placenta. Though the pathogenesis of PE remains unclear, an imbalance in the reninangiotensin and immune systems are thought to be major contributors. Bridging these two
concepts, it has recently been shown that women with PE harbor specific autoantibodies: the
angiotensin II type 1 receptor activating autoantibody (AT1-AA). These autoantibodies act as
angiotensin II and stimulate the ubiquitous AT1 receptor.
To elucidate the role of AT1-AA in the pathophysiology of PE, a model of adoptive
transfer was generated wherein AT1-AA isolated from human sera are injected into pregnant
mice. This autoantibody incites the key features of the disease in pregnant mice: increased
blood pressure, proteinuria, renal and placental abnormalities and increases in the antiangiogenic factors soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin (sEng). These
vii

experiments were also carried out in non-pregnant animals who did not share the same
symptoms. This suggests that pregnancy is a requirement for the full spectrum of preeclamptic
features. In addition, the placentas and fetuses of AT1-AA-injected mice are reduced in size.
The pups demonstrated intrauterine growth restriction (IUGR) and organ immaturity, especially
in their kidneys and livers. To elucidate the mechanism by which these preeclamptic symptoms
arise in the mouse model, the effects of increased inflammation were investigated. A multianalyte screen indicated that the autoantibody induced inflammatory cytokines. TNF-alpha, a
potent pro-apoptotic cytokine, known to be increased in both the sera and placentas of
preeclamptic women, was most elevated, and was therefore the focus of further research. When
incubated with AT1-AA, human placental explants greatly increased their production of TNFalpha. In addition, TNF-alpha-mediated apoptosis was increased due to AT1-receptor activation
in both the mouse placenta and human villous explants. Autoantibody-induced apoptosis and
TNF-alpha production could be specifically reduced by co-treatment of AT1-AA with an antiTNF-alpha antibody, losartan (an AT1 receptor blocker) or an antibody-neutralizing peptide, 7aa. In order to test the pathophysiologic relationship between AT1-AA and TNF-alpha in vivo,
the established adoptive transfer mouse model was employed. Co-injection of AT1-AA and an
anti-TNF-alpha antibody reduced the features of PE in pregnant mice, implying an important
pathogenic role for this cytokine.
Overall, when injected into pregnant mice, AT1-AA induces the clinical features of PE
and results in increased TNF-alpha production, placental apoptosis and fetal anomalies.
Blockade of these features can be partially diminished by anti-TNF-alpha treatment, an AT1
receptor blocking drug, or a peptide which specifically neutralizes autoantibody action.
Significantly, these findings could lead to a screening tool for preeclampsia as well as a
potential therapeutic strategy for this life-threatening disease of mother and child.
viii
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CHAPTER 1:

GENERAL INTRODUCTION

1

GENERAL INTRODUCTION

The classic circulating RAS pathway
Classically described in the kidney, the renin-angiotensin system, herein RAS, is a
hormone signaling cascade which regulates blood pressure and systemic electrolyte and fluid
balance. In response to decreased blood pressure and low circulating sodium chloride,
angiotensinogen, an alpha-2-globulin protein produced constitutively by the liver, is cleaved by
the enzyme renin, which is synthesized and released by juxtaglomerular cells of the afferent
renal arterioles (Fig. 1). Renin is rapidly produced and released by the macula densa [1]. The
cleavage of the 452 amino acid angiotensinogen by renin yields the ten amino acid long
peptide, angiotensin I (ANG I), and is the rate limiting step of the cascade. The biologically
inactive ANG I is then cleaved by angiotensin-converting enzyme (ACE), made primarily in
lung endothelium, to the biologically functional angiotensin II (ANG II), the eight amino acid
long effector molecule of the RAS.

ANG II exerts its effects through two major angiotensin receptors: AT1 and AT2. These
highly conserved seven transmembrane G-protein-coupled receptors share a thirty-four percent
sequence identity and have comparable affinities for ANG II [2]. The AT1 receptor is the
predominant angiotensin receptor and is responsible for the majority of ANG II signaling. Its
expression is fairly ubiquitous, and it is found abundantly in the adult kidney and on the surface
of many cell types including vascular smooth muscle cells, adrenal glands and
syncytiotrophoblasts [3-5]. It is coupled to a Gq protein, whose stimulation results in increased
intracellular calcium resulting in vasoconstriction, increased sympathetic activity and sodium
and water retention. The minor angiotensin receptor, AT2, is not highly expressed in the adult
2

but predominates during fetal development, with its expression decreasing throughout the
neonatal period [6]. AT1 is more abundant than AT2 in the adult kidney [2]. Stimulation of the
AT2 receptor inhibits cell growth, increases apoptosis, causes vasodilation and regulates fetal
tissue development [7].

Figure 1. The renin-angiotensin system (RAS) cascade and PE. Though its end-effects are increased, ANG
II, the key effector molecule of the RAS, is not upregulated in PE. The autoantibody, AT1-AA, through AT1
receptor activation, may lead to the maternal features, such as vasoconstriction and increased blood pressure,
observed in the disease. ADH, antidiuretic hormone; PAI-1, plasminogen activator inhibitor-1; sEng, soluble
endoglin; sFlt-1, soluble fms-like tyrosine kinase.

In addition to the classic circulating RAS, there is extensive evidence indicating that
local renin-angiotensin systems are present in many organs, such as the heart, ovary, and
placenta [8, 9]. Though these local systems may contribute to RAS functions, they are not the
focus of this thesis, which will concentrate on the overall systemic effects of the RAS during
pregnancy.
3

Uncomplicated pregnancies require strict regulation of the RAS
During an uncomplicated pregnancy, the RAS undergoes specific changes. The
upregulation of renin is the first change to occur, mainly due to the extra-renal release locally
by the ovaries and maternal deciduas [10]. As it grows, the placenta produces estrogen, a
steroid hormone vital to sustain pregnancy. Estrogen also increases angiotensinogen synthesis
by the liver, leading to increased serum ANG II [11]. The only RAS component that is reported
to decrease during normal pregnancy is ACE [12-14]. Table 1 compares serum RAS
component levels between non-pregnant women and pregnant women with no complications.
Many physiologic changes occur in the cardiac and renal systems during gestation to
meet the expanding needs of blood supply and nutrients. Interestingly, during normal
pregnancy, maternal blood pressure is often slightly decreased in the second trimester and
returns to baseline by delivery [15]. This phenomenon is puzzling, as ANG II levels are
elevated throughout gestation [16]. The historic study by Assali et al. revealed that healthy
pregnant women are refractory to the vasopressor effects of ANG II [17]. In fact, pregnant
women require twice as much ANG II by intravenous infusion as compared to their nonpregnant counterparts in order to achieve similar vasomotor responses [17, 18]. Some believe
that this decreased ANG II sensitivity is explained by the presence of increased progesterone
and prostacyclins during pregnancy which act a vasodilators [19]. In addition, AT1 receptors
are in a heterodimeric state in ANG II sensitive conditions, whereas during an uncomplicated
pregnancy, they are monomeric and can be inactivated by reactive oxygen species (ROS) [20].
Taken together, these studies explain why a normotensive pregnant woman may be insensitive
to ANG II stimulation.

4

A healthy placenta is a dynamic organ which undergoes many changes throughout
gestation that are essential to maintain a normal pregnancy. Placental trophoblasts are AT1
receptor-rich, making them responsive to changes in the RAS [4]. Several recent studies
demonstrate that AT1 receptor signaling regulates several genes responsible for normal
trophoblast invasion (e.g., plasminogen activator inhibitor-1, PAI-1) [21-23] and angiogenesis
(soluble fms-like tyrosine receptor-1, sFlt-1; soluble endoglin, sEng) [24-26]. In addition, AT1
receptor stimulation also results in NF-kappa B (NFκB) and NADPH-oxidase synthesis by
trophoblasts [27]. These RAS-related changes in the placenta are necessary in maintaining an
uncomplicated pregnancy. Through the evidence provided in human studies, it is clear that the
systemic and placenta-specific RAS undergo specific and necessary changes in order to sustain
a healthy pregnancy.

Dysregulation of the RAS in preeclamptic women
Preeclampsia (PE) is a disorder of pregnancy characterized by new-onset maternal
hypertension and proteinuria. This life-threatening condition affects approximately 7% of
pregnancies and results in substantial maternal and neonatal morbidity and mortality [28]. In its
severe form, the clinical symptoms of PE may include cerebral edema, renal failure and the
HELLP (Hemolysis, Elevated Liver enzymes and Low Platelets) syndrome. It can be fatal and
is the cause for approximately 18% of all pregnancy-related maternal deaths in the US each
year [29-31]. This disturbing percentage of maternal mortality is due to the fact that treatment
for PE is hampered by a paucity of screening or diagnostic tests. For centuries, the only cure for

5

Serum RAS Component

Normotensive Pregnancy

Preeclamptic Pregnancy

References

Renin
Angiotensin I
ACE
Aldosterone
ANG-(1-7)
Angiotensin II
Angiotensin II sensitivity
AT1-AA presence
AT1-AA bioactivity
AT1 receptor

++
++
++
++
++
Refractory
< 30%
Low
+, homodimer

+
+
+
+
Sensitive
> 90%
High
++, heterodimer

Hsueh [10] , Langer [16]
Merrill [12], Langer [16]
Merrill [12], Oats [13, 14], Langer [16]
Brown [32], Langer [16]
Merrill [12]
Langer [16]
Gant [19], Abdul-Karim [18]
Wallukat [33], Siddiqui [34]
Siddiqui [34]
Herse [35], AbdAlla [20]

sFlt-1

++

+++

Maynard [36], Levine [37], Zhou [25, 38]

sEng

++

+++

Venkatesha [39], Zhou [26, 38]

PAI-1

+

++

Estelles [40], Shaarawy [41], Bobst [21]

Tissue Factor

+

++

Estelles [40], Dechend [42]

NADPH oxidase, ROS

+

++

Hubel [43], Dechend [27]

Molecules under
partial AT1r regulation

Legend: ++
+
-

Greatly increased over non-pregnant
Slightly increased over non-pregnant
Decreased compared to non-pregnant

Table 1: Comparison of circulating molecules in normotensive and preeclamptic pregnancies versus non-pregnant women. In general, circulating
RAS molecules are increased in normal pregnancies versus the non-pregnant state. Though in most serum RAS components, there is a slight increase in
preeclamptic women over the non-pregnant state, they are decreased as compared to normotensive pregnant women. Many of the other molecules known
to be increased in PE are regulated by the AT1 receptor. PAI-1, plasminogen activator inhibitor-1; ROS, reactive oxygen species; sEng, soluble endoglin;
sFlt-1, soluble fms-like tyrosine kinase.
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the disorder is delivery of the infant and placenta. The underlying pathogenic mechanisms of
PE remain largely undetermined, however uteroplacental ischemia and the subsequent release
of soluble factors, such as sFlt-1, from the placenta into the maternal circulation are thought to
contribute to the systemic syndrome [44].
The regulation of the RAS in PE differs from that in healthy pregnancies. It is generally
accepted that circulating RAS components increase in an uncomplicated pregnancy. Though
elevated over the non-pregnant condition, preeclamptic women have lower circulating levels of
RAS components than do their normotensive pregnant counterparts [16, 32, 45] (Table 1). Two
exceptions to these decreases should be noted. First, ACE is reportedly lower in pregnant
woman as compared to non-pregnant women, and Merrill et al. demonstrated that ACE levels
are approximately equal in normotensive and preeclamptic women [12, 13]. Secondly, ANG(1-7), a vasodilator produced by several tissues such as kidney, heart, hypothalamus and ovary,
is significantly decreased in PE [12]. Its exact role in the RAS and the regulation of a healthy
pregnancy remains undefined. Though it may act through its own receptor, ANG-(1-7) interacts
primarily with AT1 and AT2 receptors [46, 47]. Furthermore, women experiencing an
uncomplicated pregnancy demonstrate a relative vascular insensitivity to ANG II. Preeclamptic
women, however, exhibit increased ANG II sensitivity in their adrenal cortex and vascular
system [19, 48]. This can be explained by the heterodimerization of the AT1 receptor in PE,
whereas in healthy pregnancies, the receptors are monomeric and can be inactivated by ROS
leading resulting in ANG II insensitivity [20]. In PE, the AT1 receptor forms a heterodimer
with the bradykinin receptor (B2) [20, 49] and the ROS-inactivation resistant AT1/B2
heterodimers are hyperresponsive to ANG II [20, 50, 51]. Future investigation into the
heterodimeric receptors as the symptoms of PE subside postpartum is necessary. Overall, these
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findings indicate that the profile of RAS components in a preeclamptic woman differs greatly
from that of a healthy pregnant woman.

A source of excess AT1 receptor activation: the Angiotensin II type I receptor Agonistic
Autoantibody (AT1-AA)
Though the dysregulation of the RAS in PE is largely accepted, the causative factors
leading to this imbalance remain unidentified. Though ANG II levels are reportedly decreased
in preeclamptic women as compared to normotensive pregnant women (Table 1) [19, 48], these
patients exhibit symptoms which could be attributed to excess AT1 receptor activation, such as
hypertension and renal dysfunction. The exact cause of this excess activation is unknown. One
explanation to this puzzling feature is the recent discovery by Wallukat et al. that preeclamptic
women harbor an autoantibody which stimulates the AT1 receptor [33]. Through excess AT1
receptor activation, the angiotensin II type I receptor agonistic autoantibody (AT1-AA) could
interfere with the normal function of the RAS in the pregnant woman and lead to preeclamptic
symptoms. If true, this would suggest an important role of AT1-AA in the pathogenesis of PE.
Many recent studies have shown that by activating AT1 receptors on a variety of cell types,
these autoantibodies could increase certain factors which lead to preeclamptic pathophsyiology
such as endothelial cell dysfunction and vascular damage [44, 52, 53]. Examples of the possible
contributions of AT1-AA in the pathogenesis of PE are reviewed in the subsequent section and
summarized in Figure 2.

8

Figure 2. Possible roles of the autoantibody in the maternal and fetal features of PE. The autoantibody,
AT1-AA, through excess AT1 receptor activation, may contribute to the maternal and fetal features observed in
PE. AT1–AA, angiotensin-II type I receptor agonistic autoantibody; IUGR, intrauterine growth restriction; PAI-1,
plasminogen activator inhibitor-1; sEng, soluble endoglin; sFlt-1, soluble fms-like tyrosine; TF, tissue factor.

In vitro studies linking AT1-AA to the maternal syndrome of PE
A growing body of evidence indicates that the autoantibody, through the upregulation
of AT1 receptor signaling, may contribute to the maternal symptoms of PE in a variety of ways.
Wallukat et al. have shown that AT1-AA can stimulate rat cardiomyocyte contraction rate [33].
In addition, several in vitro studies suggest that AT1-AA may regulate the following molecules:
sFlt-1, sEng, PAI-1, ROS, NADPH oxidase, intracellular calcium and tissue factor (TF).

9

a) Excess sFlt-1 secretion and impaired angiogenesis is induced by AT1-AA.
Soluble fms-like tyrosine kinase-1 (sFlt-1) has recently been brought to the forefront of
factors contributing to preeclamptic features [37, 54]. sFlt-1 is a splice variant of VEGFR-1 and
is a secreted soluble form of the receptor which lacks the transmembrane and cytoplasmic
domains. It binds to free vascular endothelial growth factor (VEGF) and placental growth
factor (PlGF) thereby inhibiting their angiogenic actions [55-57]. This soluble factor may
contribute to the maternal symptoms of PE by impairing angiogenesis, leading to placental and
renal dysfunction.
The soluble factor sFlt-1 is increased in both the circulaton and the placentas of
preeclamptic women [36, 52, 58-60]. Circulating sFlt-1 is elevated in preeclamptic women as
compared to normotensive pregnant women [37, 61], and is thought to be liberated primarily by
the placenta. In the placenta itself, Roberts et al. report that sFlt-1 secretion is increased two- to
five-fold in preeclamptic women over placentas from normotensive pregnancies [36, 58, 59].
The ratio of sFlt-1, VEGF and PlGF are important in the angiogenic balance of the placenta.
Nagamatsu et al. have shown that placental hypoxia specifically induces sFlt-1, and not VEGF
[62]. Khaliq et al. state that hypoxic BeWo choriocarcinoma cells have decreased PlGF
expression [63]. Another study reports a diametric expression of VEGF and PlGF during
normal gestation, and others demonstrate a cytotrophoblastic increase in VEGF and decrease in
PlGF in PE [64, 65]. Total VEGF expression may increase during normal pregnancy, but when
high sFlt-1 levels are apparent, the free VEGF decreases, which results in diminished
angiogenic capability [66]. Therefore, excess placental sFlt-1 production leads to decreased
free VEGF on a background of low PlGF. This results in an anti-angiogenic state overall in the
placenta which could contribute to the small, hypoxic organs described in preeclamptic women.
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The autoantibody, AT1-AA, could contribute to the excess sFlt-1 in PE. The placenta
produces sFlt-1 through AT1 receptor stimulation of trophoblast cells via the calcineurin-NFAT
pathway even during a normal gestation [25]. Therefore through the additional stimulation of
the AT1 receptor by the autoantibody, excessive sFlt-1 production may occur. Zhou et al. report
that sFlt-1 secretion can be induced by autoantibodies derived from preeclamptic patient sera in
human placental explants and a human trophoblast cell line [24, 25]. This suggests that AT1AA can additively contribute to the excess sFlt-1 secretion reported in preeclamptic patients.
Excess sFlt-1 may not only cause placental damage, but may also lead to kidney abnormalities.
Maynard et al. report that pregnant rats infused with sFlt-1 induces a preeclamptic-like state.
These rats demonstrate increased blood pressure, proteinuria and renal histopathologic changes
similar to those observed humans, such as glomerular endotheliosis [36]. Thus, through its
induction of sFlt-1, AT1-AA may contribute to the kidney dysfunction observed in PE. Taken
together, these findings suggest that the autoantibody, through AT1 receptor activation, can
additively contribute to the excess sFlt-1 secretion reported in preeclamptic patients.
b) Soluble endoglin is induced by AT1-AA
Endoglin (Eng, or CD-105) is a cell-surface co-receptor for transforming growth factor
(TGF)-β1 and TGF-β3 which is highly expressed in endothelial cells and syncytiotrophoblasts
[67, 68]. Soluble endoglin (sEng), a soluble form of the TGF-β receptor, is the second major
anti-angiogenic factor recently implicated in the maternal syndrome of PE [69]. The balance of
this TGF-β antagonist becomes undone in PE as sEng is secreted in excess by the placentas of
preeclamptic women [61, 70, 71]. By impairing the ability of TGF-β1 to bind its receptors,
downstream signaling, including the activation of eNOS and vasodilation, do not occur [39,
72]. In this way, sEng contributes to the disease features by dysregulating TGF-β signaling
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pathways in the vasculature. Venkatesha et al. have definitively shown that sEng works
additively with sFlt-1 to contribute to severe preeclamptic features in pregnant rats [39].
Moreover, Zhou et al. have recently shown that sEng can be induced by AT1-AA in human
villous explants [73]. Since this molecule has been proven to contribute to disease features in
other experimental models, and some through AT1 receptor activation, the autoantibody may
induce this factor in vivo and lead to the symptoms of PE.
c) AT1-AA induces excess PAI-1 secretion
Plasminogen activator inhibitor-1 (PAI-1) is another factor related to the pathogenesis
of PE [40, 74]. PAI-1 is a serine protease which inhibits urokinase-like plasminogen activator
(uPA) and decreases the conversion of plasminogen to plasmin resulting in decreased
fibrinolysis and increased fibrosis. It also indirectly inhibits extracellular matrix breakdown via
matrix metalloproteinases [75]. In the placenta, by decreasing fibrinolysis and extracellular
matrix digestion, PAI-1 could lead to shallow trophoblast invasion, a hallmark of preeclamptic
placentas. Studies have shown that by activating trophoblastic AT1 receptors, AT1-AA elevates
PAI-1 levels [21, 76] and decreases trophoblast invasion in vitro [21, 22]. In the kidney, ANG
II partially controls mesangial cell PAI-1 production [77, 78]. A series of in vitro experiments
by Bobst et al. revealed that AT1-AA, through AT1 receptor activation on cultured human
mesangial cells, increase PAI-1 secretion [21]. The accumulation of PAI-1 could result in
decreased extracellular matrix degradation and subendothelial and subepithelial fibrin deposits,
thereby contributing to the kidney damage observed in PE [79, 80]. Excess glomerular fibrin
deposition decreases the kidney’s filtration capability which contributes to proteinuria [81, 82].
Therefore, by overstimulating the RAS, AT1-AA increase PAI-1 in both the placenta and
kidney and lead to decreased fibrinolysis and extracellular matrix breakdown which could
contribute to the organ damage and symptoms associated with the disorder.
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d) ROS production is increased by AT1-AA
Reactive oxygen species (ROS) are a physiologic by-product of aerobic respiration and
regulate cellular functions through redox reactions [83]. When ROS aberrantly accumulate, the
cell becomes burdened by an overload of non-specific damage to DNA, proteins and lipids.
During pregnancy, this process of oxidative stress could directly lead directly to organ damage.
In addition, ROS can act as teratogens and could harm the developing fetus, especially during
organogenesis [84, 85]. In PE, the generation of ROS is increased and may contribute to endorgan damage [43]. Excess AT1 receptor activation leads to increased NADPH oxidase thereby
inducing intracellular ROS. Dechend et al. confirmed that NADPH oxidases are elevated in
preeclamptic placentas and that the autoantibody increases ROS through this mechanism in
vascular smooth muscle cells and placental trophoblasts [27]. In addition, this group
demonstrated that AT1-AA upregulated NFκB and confirmed elevated ROS production both in
and around placental blood vessels. Therefore, the autoantibody, by activating NADPH
oxidase, could lead to the increased ROS production observed in PE.
e) Intracellular calcium release is induced by AT1-AA
Increased intracellular calcium levels are reported in the erythrocytes, lymphocytes and
platelets of preeclamptic women [86-88]. Basal free intracellular calcium was shown by Haller
et al. to be elevated in the platelets of PE women. The cation was also elevated in the both the
lymphocytes and erythrocytes of these patients in comparison to normotensive pregnant women
[87, 89]. Thway et al. investigated the possible role of AT1-AA in the elevation of free
intracellular Ca2+ [90]. This group found that IgG isolated from preeclamptic patients was
capable of activating AT1 receptors and consequently increasing intracellular calcium, whereas
IgG derived from normotensive pregnant women could not. The increased intracellular Ca2+
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resulted in the activation of the NFAT transcription factor [90]. These studies suggest that the
autoantibody may contribute to increased calcium in the cell, and could regulate the
downstream signaling pathways activated in PE.
f) AT1-AA may contribute to hypercoaguability
Tissue factor (TF), the initiating protein of the extrinsic path of coagulation, is elevated
in PE [40, 74]. The overexpression of this transmembrane protein may induce vascular damage
and could result in the state of hypercoaguability, and rarely disseminated intravascular
coagulation (DIC) in some severely preeclamptic patients. AT1 receptor activation, via AT1-AA
has been shown to increase TF expression in vascular smooth muscle cells [42] and monocytes
[91]. In this way, AT1-AA may play a role in the hypercoaguability associated with PE by
upregulating TF expression in vascular smooth muscle cells and monocytes.

Overriding hypothesis
Taken together, these series of experiments lead to the overriding hypothesis of this
dissertation: the autoantibody, AT1-AA, contributes to the pathogenesis of the PE through
excess AT1 receptor activation. In order to prove this theory, in this thesis I will explore how
biologically active autoantibodies from preeclamptic women can be purified and upon injection
into pregnant mice, incite the maternal, placental and fetal features of this disease. Using both
in vitro and in vivo systems, it will be illustrated how AT1-AA induce several detrimental
factors associated with PE, including increased inflammation. It will be shown how blockade of
AT1 receptor activation, specific autoantibody neutralization or blockade of TNF-α prevents
disease features in adoptively transferred mice, human placental explants in culture and a
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cultured human trophoblast cell line. Overall, these findings could have tremendous diagnostic
and therapeutic impact in the management of PE.
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CHAPTER 2:

EXPERIMENTAL PROCEDURES
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EXPERIMENTAL PROCEDURES

Patient consent and collection of samples
The human medical data and materials used in these experiments were acquired from
patients admitted to Memorial Hermann Hospital which were identified by the Obstetrics and
Gynecology faculty of the University of Texas Medical School at Houston. Based on the
criteria defined by the National High Blood Pressure Education Program Working Group
Report [92], some pregnant patients were diagnosed with severe PE. Table 2 reports the
clinical characteristics of study participants. One of the two inclusion criteria was blood
pressure readings of ≥160 mm Hg systolic or ≥110 mm Hg diastolic in a pregnant woman after
20 weeks gestation age (WGA). Qualifying blood pressure measurements must have been
taken on two separate occasions, ≥6 hours apart. The second requirement for diagnosis was an
absolute level of proteinuria measuring ≥300 mg protein in a urine specimen collected over 24
hours or ≥30 mg/dL (≥1+ reading on dipstick) in a random urine determination in the absence
of a urinary tract infection. The preeclamptic women used in this work had no previous history
of hypertension. The control patients used were normotensive pregnant women undergoing
uncomplicated pregnancies and normal term deliveries or elective caesarean sections. Patients
were approached for consent in the pre-partum or early intrapartum period. Blood samples
were drawn from all participants before parturition, allowed to clot and then centrifuged at
18,000g at 4ºC for 20 minutes. The sera were collected, aliquoted and then stored at -80ºC. In
some cases, cord blood was also collected from participants at the time of delivery and was
handled in the same manner as the maternal blood. The research protocol, including the written
informed consent form, was approved by the University of Texas Health Science Center at
Houston Committee for the Protection of Human Subjects (CPHS), in Houston, Texas, USA.
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NT

PE

49

54

27.7 ± 7.7

30.6 ± 6.2

Black

33

36

White

19

14

Hispanic

47

46

Other

1

4

Gravity

2.1 ± 0.9

1.9 ± 1.1

BMI

31.2 ± 3.4

37.1 ± 6.7

Weeks gestational age

38.1 ± 2.4

31.3 ± 5.0

Systolic BP (mmHg)

121 ± 4

173 ± 16*

Diastolic BP (mmHg)

74 ± 7

103 ± 13*

Proteinuria (mg/24h)

<300

4572 ± 1326*

0.14 ± 0.04

5.17 ± 1.07*

Median AT1-AA bioactivity
(fold induction over basal)

0.05

1.95*

AT1-AA bioactivity range
(low, high; fold induction over basal)

0, 0.5

0.5, 11.9

16.1 ± 2.9

48.0 ± 2.9*

23.6

44.2*

0, 25.9

32.8, 76.8

n
Age (y)
Race (%)

Mean AT1-AA bioactivity
(fold induction over basal)

Mean serum TNF-α (pg/ml)
Median serum TNF-α (pg/ml)
Serum TNF-α range (low, high; pg/ml)

Table 2: Patient clinical characteristics. This table illustrates that the blood pressure, proteinuria
and TNF-α levels are elevated in preeclamptic (PE) women, as compared to the normotensive (NT)
pregnant women used as controls. The bioassay indicating AT1 receptor activation due to the
autoantibody (as measured by luciferase activity) is also increased in preeclamptic women. The
category mean or median is indicated (± SEM, where applicable). * P<0.01 versus normotensive
pregnant women.  For these variables: NT, n=16; PE, n=20.
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Reagents
RPMI 1640 cell culture medium plus L-glutamine, antibiotics (penicillin-streptomycin
100X and geneticin G418, 50 mg/ml), bovine serum albumin (BSA), fetal bovine serum (FBS)
were purchased from Invitrogen Life Technologies. Human angiotensin II (ANG II) was
acquired from Sigma. Merck & Co., Inc. generously provided losartan (Cozaar). The seven
amino acid peptide (7-aa) which corresponds to the second extracellular loop of the human
AT1 receptor (AFHYESQ) was purchased from Baylor College of Medicine Protein Chemistry
Core Laboratory.

Purification of total immunoglobulin G from patient sera
Total IgG fractions were purified from pregnant patient sera as previously described
[34, 38]. Briefly, 200µl GammaBind G Sepharose matrix beads (Amersham Biosciences) were
loaded into a PolyPrep chromatography column (BioRad). Before applying any sera, the
column was washed repeatedly with wash buffer (50mM tris-HCl, 0.02% NaN3, ph 7.4) until
the column flow-through was neutral. Then, 200µl of human sera was applied to the column,
and after an incubation of 30 minutes, eluted using 600µl of eluent buffer (100mM glycineHCl, pH 2.7) in accordance to the manufacturer’s recommended protocol. The isolated total
IgG was mixed with 40µl of neutralization buffer (1M tris-HCl, pH 9.0) to establish a neutral
pH and was stored at -80ºC. Each fraction was then assessed for the presence of the
autoantibody using a luciferase reporter assay described below. In the experiments reported
here, IgG fractions from individual patients were used separately and were not pooled.
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Affinity purification of AT1-AA using total human IgG
Some experiments described here utilize AT1-AA affinity-purified from total human
IgG. 7-aa, the epitope peptide corresponding to a segment on the second extracellular loop of
the AT1 receptor, can block autoantibody-induced receptor activation [33] and therefore
suggests a physical association between these autoantibodies and AT1 receptors. This
presumed physical association was the basis of an affinity purification strategy used in
obtaining highly enriched preparations of AT1-AA. A GST fusion protein containing a 27-aa
peptide (GST-27mer) which encodes the entire second extracellular loop of the AT1 receptor
(accession code: NM_009585.2) was generated. The construction, expression and use of the
GST-27mer:AT1-receptor fusion protein in the affinity purification of AT1-AA was carried out
as previously described [38]. Briefly, BL21 DE3 E. coli cells (Stratagene) were transformed
with the pGEX-4T-1 GST expression vector (Promega) containing the GST-27mer:AT1receptor fusion protein. After induction, the cells were collected and the GST-27mer-AT1
receptor fusion protein was isolated using glutathione beads (Amersham Biosciences). The
expression of the fusion protein was confirmed using western blot. The isolated GST27mer:AT1-receptor fusion protein was then linked according to the manufacturer’s protocol to
agarose beads using the microlink protein coupling kit (Pierce) which were then used in
affinity chromatography columns. Total IgG was isolated from patient sera (as described
above) and was loaded onto affinity chromatography columns. The total IgG incubated on the
columns for 3h at room temperature. The IgG bound to the columns (AT1-AA) was eluted by
centrifugation after collection of the flow-through fraction. To confirm the presence of AT1AA, the eluted and flow-through fractions were tested for their ability to bind to the AT1
receptor. Only the eluted fraction (the affinity-purified AT1-AA) was capable of binding to
AT1 receptors transferred onto nitrocellulose membranes, whereas the flow-through fraction
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could not bind to the AT1 receptor and was not detectable by western blot. Furthermore, to
confirm that the eluted fraction retained biologic activity, the fractions were tested for their
ability to activate luciferase using an established bioactivity assay described below. Only the
eluted fraction from total IgG from preeclamptic patients (containing AT1-AA) could stimulate
luciferase activity and the other fractions were unable to do so. This fraction, containing AT1AA, was used in subsequent experimentation.

Luciferase bioactivity assay for the presence of AT1-AA
To assess for the presence and bioactivity of the autoantibody in an IgG fraction, an inhouse luciferase bioassay was employed as previously described [34, 38]. Chinese hamster
ovary cells which were stably transfected with the rat ANG II receptor type 1A (CHO.AT1A)
were generously provided by Dr. Terry S. Elton of The Ohio State University in Columbus,
OH. Cells were maintained and cultured in RPMI 1640 medium containing 5% FBS, 1%
antibiotics, 8.75 g L-proline and 100 µg/ml gentamycin at 37oC and 5% CO2. Cells were then
stably transfected with a nuclear factor of activated T cells (NFAT)-luciferase-hygromycin
phosphotransferase construct containing 4X-NFAT binding elements driving the expression of
the luciferase reporter gene. Stable transformants were maintained in the media described
above enriched with 100 µg/ml hygromycin. 1x105 CHO.AT1A cells stably integrated with
copies of the rat AT1 receptor:4X-NFAT-driven luciferase construct were evenly plated on 24well plates overnight. The next morning the media was changed to serum-free media and the
cells were treated with IgG (1:10 dilution). After 24 hours, the treated cells were lysed using
100µl of passive lysis buffer (Promega) for 30 minutes, shaking in the dark at room
temperature. Luciferase activity was measured using a Luminometer (Pharmingen) as relative
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light units (RLU) after mixing 20µl of lysate and 100µl of the Dual Luciferase system
(Promega). The data is represented as either an increased or decreased ratio of change of RLU
from the baseline (background luciferase activity of untreated cells).

Adoptive transfer: introduction of human IgG into mice
The adoptive transfer of AT1-AA or purified IgG derived from normotensive pregnant
women into mice was carried out as previously described [38]. Briefly, C57Bl/6J non-pregnant
or pregnant mice (18-22 g; aged <8 weeks, Harlan) were used all mouse experiments. Mice
anesthetized with sodium pentobarbital (50 mg/kg i.p.) were injected with 20µg affinity
purified IgG or 100µl total IgG via retro-orbital sinus injection. Volumes less than 200µl
represent less than 10% of mouse total blood volume and should not alter hemodynamics. If
the experiment required injection into pregnant mice, this was done so on embryonic day (E)
13 and then again on E14. E13 was selected as this developmental stage in mouse pregnancy is
comparable to the timeframe at which preeclamptic symptoms may occur in humans, and E13
is the earliest point at which mouse pregnancy is reliably confirmed. Also, when autoantibody
injections were performed on E8-10, high rates of embryonic resorption were encountered.
Some neutralization experiments required the simultaneous co-injection of the autoantibody
with either losartan (8 mg/kg i.v.), or 7-aa, the epitope peptide, (50 mg/kg i.v.). Some dams
were co-injected with purified human IgG and a goat polyclonal antibody raised against TNF-α
(Abcam). They received 0.6µg/g body weight intraperitoneal shots of the anti-TNF-α antibody
daily. This dosage was adapted from experiments previously described [93-96]. As controls,
one group of mice was injected with the anti-TNF-α antibody (Abcam, 0.6µg/g body weight
i.p. daily) alone, but with no accompanying purified human IgG and another was co-injected
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with a goat IgG isotype (Abcam, 0.6µg/g body weight i.p. daily) and PE-IgG as described
above in this section.

Blood pressure and proteinuria measurement in mice and fetal organ collection
The systolic blood pressure of all mice was measured at the same time daily (+/- 1h) by
an automated carotid catheter-calibrated tail-cuff system (Kent Scientific). The mice were not
anesthesized and once placed in the restrainer, were given a period of about fifteen minutes to
acclimatize. Using a warming pad, their temperatures were monitored and controlled to be
stable between 30-35oC (Kent Scientific). Twenty blood pressure cycles were measured daily
using the automated system and then averaged. Proteinuria was determined by the ratio of
urinary albumin to creatinine. Urine from each mouse was collected for analysis using
metabolic cages (Nalgene) for 24h prior to sacrifice. Urinary albumin was quantified using an
ELISA and creatinine was assessed using a picric acid colormetric kit (Exocell). If pregnant,
the dams were sacrificed on E18, or if non-pregnant, they were sacrificed five days post the
initial injection. At the time of sacrifice, the sera and organs of the female mice were collected.
If pregnant, the placentas and fetal mouse organs including blood were also collected. Fetal
blood was pooled from the all littermates, as the extractable blood volume is minimal. Pups
born in litters of six to eight were analyzed in the fetal mouse experiments. The animal studies
were approved of by the Animal Welfare Committee of the University of Texas Health Science
Center at Houston, in Houston, Texas, USA.
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ELISAs
For the screening of inflammatory markers, mouse serum was diluted 1:25 for use in the
qualitative Multi-Analyte ELISArray Kit (SABiosciences). Human and mouse serum TNF-α,
sFlt-1 and sEng were quantified using species-specific ELISA kits which are commercially
available (R&D Systems). These ELISA procedures were carried out according to the
manufacturers’ protocol and the optical density was determined at 450 nm and corrected at 570
nm. All assays were performed in duplicate at minimum and the protein concentrations were
derived from a standard curve generated from known amounts of the recombinant protein.
Human IgG concentration was determined in maternal and fetal mouse circulation, by diluting
sera 300-fold and quantified by a commercial ELISA kit (Pierce Biotechnology Inc.). For the
standard curve experiment, either 0.0 (control), 0.5 or 5.0 µg/ml of anti-TNF-α (Abcam) was
added to known concentrations of recombinant mouse TNF-α and the mixtures were assessed
by ELISA for its ability to detect either bound or free cytokine (R&D Systems).

Protein extraction and quantification
Proteins for analysis by western blot were collected from cultured cells and from frozen
tissues in the following manner. Cells were grown to ~80% confluence in 24-well plates (see
below), media was removed and then cells were washed once with cold PBS. While the plate
was on ice, 200µl of lysis buffer (Millipore) was added to the each well. After 2 minutes, the
cells were scraped off the base of the wells using a plastic well scraper. The resultant mixture
of cell lysate, fragments and buffer were collected into eppendorf tubes and placed on ice for
30 minutes. For frozen tissues, 500µl of lysis buffer (Millipore) and 3µl of a protease inhibitor
cocktail (Sigma) was added to the tissue tubes upon removal from the liquid nitrogen storage
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tank. While on ice, the tissues were sonicated for ~20 seconds at 20% amplitude. Once a
homogenous mixture was obtained from either cell or tissue lysates, it was centrifuged for at
least 15 minutes at 4oC at 15,000 rpm. The pellet was discarded and the supernatant containing
the protein was transferred to a new tube and stored at -80oC. Before use, the protein
concentration was checked by mixing 10µl of sample with 200µl of a protein assay reading
solution (Bio-Rad) in duplicate in a 96-well plate. The mixture was allowed to sit at room
temperature for 5 minutes and then the absorbance was read at 595 nm using a
spectrophotometer. Protein concentrations were calculated using BSA standards of 0.1, 0.2, 0.4
and 0.5 mg/ml and generating a standard curve.

Western blot analysis
Western blot analysis was used to determine the presence of AT1-AA in human sera as
previously described [38]. Briefly, protein extracted from CHO.AT1A cells (CHO-NFAT cells
which were stably transfected with the rat AT1 receptor gene) was run on a 10% SDS-PAGE
gel (30µg/well) and then transferred onto a nitrocellulose membrane. After the transfer, the
membrane was cut to strips, blocked with 5% non-fat milk and then probed with purified
human total IgG (1:10 dilution) and mouse anti-human IgG:horse peroxidase (HRP) (1:5000
dilution; Jackson ImmunoResearch Laboratories, Inc.), to determine if the isolated IgG had the
capability of binding the AT1 receptors transferred onto the nitrocellulose strips. As a positive
control, one strip was probed with an anti-AT1 receptor antibody (1:1000 dilution; Santa Cruz
Biotechnology) and goat anti-rabbit IgG:HRP (1:5000 dilution; Jackson ImmunoReseach
Laboratories, Inc.). Fetal mouse sera were also analyzed for circulating human IgG in a similar
manner. Fetal mouse serum (12µl) was run on a 10% SDS-PAGE gel and transferred to a
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nitrocellulose membrane which was then probed with a mouse anti-human IgG:HRP antibody,
as above. Apoptotic markers were assessed by western blot analysis in mouse and human
placentas. Rabbit anti-human or anti-mouse primary antibodies against Bax, a pro-apoptotic
protein (23 kDa), and Bcl-2, an anti-apoptotic protein (26 kDa), were both used in a 1:200
dilution (Santa Cruz Biotechnology). β-actin, a housekeeping gene (43 kDa), was run as a
loading control (Santa Cruz Biotechnology). All western blot signals were detected by ECL kit
(Amersham Biosciences). The relative densiometry was assessed by the Storm 840
Phosphorimager and the associated ImageQuant TL analysis software (GE Healthcare).

Human placental explant culture
Placentas were obtained from normotensive pregnant women who experienced an
uncomplicated pregnancy and underwent either an elective term cesarean section, or a normal
term birth at Memorial Hermann Hospital in Houston, Texas. The culture system described
here was adapted from Ahmad, et al. [97]. Upon delivery, the placentas were placed in a sterile
container on ice and transferred to the laboratory where they were immediately submerged in
and flushed with phenol red-free DMEM containing 0.2% BSA and 1% antibiotics. Villous
explant fragments (~5-10mm3) were dissected and transferred into 24-well culture plates for
overnight equilibration at 37˚C and 5% carbon dioxide. All of the manipulations on the first
day were performed within thirty minutes of delivery. The next morning, the dissected explants
were incubated with either saline, ANG II (100nM) or IgG purified from preeclamptic or
normotensive pregnant women (1:10 dilution). Some explants were co-incubated with human
IgG and either losartan (5µM) or 7-aa (1µM). After 24h, the culture media was siphoned from
the wells and stored at -80˚C. At this time, the placental explants were either lysed and their
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protein was collected for western blot analysis or fixed for further histologic or
immunohistochemical analysis.

Human trophoblast cell culture
An immortalized human trophoblast cell line, HTR-8/SVneo cells [98], were grown to
70-80% confluence using RPMI 1640 cell culture media with antibiotics, counted and then
plated in Lab-Tek 8-well chamber slides (Nunc Inc) at 2x104 cells per well overnight. The
following day, serum-free media was added and cells were incubated with either ANG II
(100nM) or IgG derived from either normotensive pregnant or preeclamptic women (1:10
dilution) and cultured for an additional 24 hours. Some experiments required the cells to be
cultured with human IgG as well as either losartan (5µM) or the 7-aa, the seven amino acid
epitope peptide (1µM). After the overnight incubation, cells were lysed and their lysates were
collected for analysis of Caspase 3 activity or permanently fixed to the slide for TUNEL or
routine immunohistochemistry staining.

Histologic analysis
The kidneys, livers and placentas of sacrificed pregnant mice, and the kidneys and
livers of their pups were harvested, fixed and processed as previously described [38, 99].
Briefly, the fresh tissues were fixed in either a 4% formaldehyde solution (Fisher Scientific) or
a zinc solution fixative solution (BD Biosciences) for 36-48h at room temperature. The fixed
samples were then washed twice with PBS for 30 minutes, dehydrated, infiltrated and
embedded in paraffin using standard techniques. Four micron serial sections were cut from
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paraffin blocks and stained with Hematoxylin and Eosin (H&E), Periodic acid-Schiff (PAS) for
glycogen, or Masson’s Trichrome for collagen, all by standard techniques, or left unstained for
further analysis.
The number of glomeruli or megakaryocytes in fetal mouse kidneys or liver,
respectively, was assessed by blindly counting the number of glomeruli or megakaryocytes in
10 random high power microscopic fields per section and then averaging this number for the
respective pup. For immunohistochemical detection of complement cascade factor C3 in both
mouse kidneys and placentas, a primary rat anti-mouse C3 monoclonal antibody was used in a
1:50 dilution (Lifespan Biosciences) after antigen retrieval, using the BD Retriveagen A
solution (BD Biosciences). The anti-C3 monoclonal antibody detects C3, C3b, C3d and iC3b.
An anti-rat IgG horseradish peroxidase kit was used with DAB detection (BD Biosciences).
CD-31 staining in mouse tissue was achieved using a rat anti-mouse CD-31 antibody (BD
Pharmingen). Dissected tissues were incubated with a zinc fixative (BD Pharmingen) overnight
at room temperature and then subsequently sectioned and prepared on slides. A 1:50 dilution of
the primary antibody was used and an anti-rat IgG horseradish peroxidase kit was employed for
detection (BD Pharmingen). The counterstain used was methyl green by standard techniques.
Immunofluorescence for the presence of human IgG was assessed using rabbit anti-human
IgG:FITC (1:30; Dako), visualized as green when excited at 515-565 nm. The sections were
counterstained with five drops of a nuclear stain, 4’,6-diamidino-2-phenylindole (DAPI) which
is visualized as blue when excited at 360 nm (Abbott Molecular). Quantification of the
immunohistochemical staining was achieved using the Image-Pro Plus 6.3 software (Media
Cybernetics). The density of brown stain (positive CD-31) was measured. The average
densities of 10 areas per placenta were averaged and the SEM was calculated. Four placentas
were selected from each mouse and eight mice were used for each variable.
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Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
Four micron sections were cut from paraffin-embedded HTR-8/SVneo cells, mouse or
human placental tissue collected and treated as described above. Using standard techniques, the
sections were permanently fixed onto a glass slide, deparaffinized and re-hydrated through an
alcohol gradient. To visualize apoptosis, tissues were permeabilized using cold, fresh 0.1%
Triton X-100 in 0.1% sodium citrate and stained using a commercial kit by terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) according to the recommended
manufacturer’s protocol (Roche Diagnostics). TUNEL-positive cells were identified by green
staining under 515-565 nm fluorescent light and confirmed using cellular morphology (cell
shrinkage, nuclear fragmentation, membrane blebbing). Negative controls were performed in
parallel, where the terminal deoxynucleotidyl transferase enzyme was omitted from the
protocol. Upon completion of TUNEL staining, 4’,6-diamidino-2-phenylindole (DAPI) nuclear
stain was added to identify cells with normal nuclear morphology. DAPI is visualized as blue
when under 360 nm fluorescent light (Vector Laboratories). An apoptotic index was generated
by the quantifying the number of apoptotic nuclei (TUNEL-positive cells) per total nuclei
(DAPI-positive) x 100. These numbers were counted blindly for each sample in 10 random
microscopic fields using Image Pro Plus 6.3 software (Media Cybernetics).

Transmission electron microscopy (TEM) of mouse kidneys
Upon sacrifice of the mice, their kidneys were immediately removed. Kidney tissue
samples were dissected into 1mm3 cubes and fixed overnight in 3% glutaraldehyde. The
fragments were then rinsed, exposed to 1% osmium tetroxide and then dehydrated and
embedded in an araldite-epon mixture. Semi-thin (0.6mm) tissue sections were prepared and
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stained with uranyl acetate and lead citrate. The prepared mouse renal tissue samples were then
examined with a JEOL 1210 transmission electron microscope (JEOL Corporation).

Caspase 3 activity
Caspase 3 activity was measured using a sensitive commercial assay (Millipore). HTR8/SVneo cells were cultured (as described above), counted and then 0.5x106 cells were pelleted
and lysed to obtain the cytosolic extract, upon which the Caspase 3 activity assay was
performed according to the recommended manufacturer’s protocol. The absorbance was
measured at a wavelength of 405 nm using a spectrophotometer. The relative absorbance
correlates to the Caspase 3 activity level.

Statistical analysis
All results are expressed as mean ± SEM, however, the median may also be reported
and was indicated as such where applicable. The data were subjected to statistical analysis
using GraphPad Prism 4 software (GraphPad Software). Student’s t tests (paired or unpaired as
appropriate) were applied in two-group analysis. Differences between means of multiple groups
were analyzed by one-way analysis of variance (ANOVA) followed by a post-hoc Tukey’s
multiple comparisons test. To determine a statistical correlation between AT1-AA bioactivity
and serum TNF-α, Spearman’s rank correlation was applied and an “r” coefficient value was
obtained using the same software. A value of P<0.05 was considered significant and the
threshold for rejection of the null hypothesis.
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CHAPTER 3:

AUTOANTIBODIES PURIFIED FROM PREECLAMPTIC WOMEN
INDUCE DISEASE FEATURES IN PREGNANT MICE
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BACKGROUND

Hypertensive diseases of pregnancy and their sequelae have troubled society since their
recognition centuries ago. Since then, scientists have sought to understand the mechanisms
which bring about maternal symptoms. Derangement of the renin-angiotensin system (RAS)
has been implicated in the development of PE in pregnant women. As described earlier, many
in vitro studies implicate that increased ANG II can provoke the many of the biologic responses
pertinent to the disease via excessive AT1 receptor activation. However, in order to fully
understand the cellular interplay of this vascular disease and pathophysiologic consequences of
RAS signaling, in vivo models must be employed. Animal systems can be used for this purpose,
because the RAS of rodents and humans are remarkably similar. The mouse has two
pharmacologically identical isotypes of the AT1 receptor, AT1a and AT1b [100, 101]. Humans
have a single AT1 receptor isotype. In general, both humans and rodents demonstrate an
upregulation of RAS components in an uncomplicated pregnancy [102]. There are no reports of
the spontaneous development of PE in animals. Nevertheless, through genetic and experimental
manipulation, animal models with altered RAS have been developed and proven useful in
delineating its role in both normal and abnormal pregnancies. Examples of these models are
reviewed here in brief.

In vivo studies of the RAS and hypertensive disorders of pregnancy
Both mouse and rat models have been employed to investigate the changes in the RAS
during pregnancy. When transgenic female mice expressing human angiotensinogen were
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mated with male transgenics expressing the human renin gene, Takimoto et al. observed
transient hypertension in the dams [103]. The hypertension was maximal in late pregnancy and
resolved post-partum. These females also demonstrated other preeclamptic features, such as
glomerular damage, proteinuria and placental abnormalities. The same group investigated the
role of angiotensin receptors in mice during pregnancy. Female AT1a receptor knockout mice
expressing the human angiotensinogen gene were mated with male mice expressing the human
renin gene. The dams remained at their baseline blood pressure throughout pregnancy, and
demonstrated no preeclamptic-like symptoms, despite having intact AT1b receptors [104].
These findings suggest the regulation of the RAS is imperative to a healthy pregnancy, and in
the mouse, AT1a receptors are important for the development of hypertension and other
preeclamptic features during pregnancy in the setting of a dysregulated RAS. This group also
used their transgenic mouse model to determine the timing of renin release in pregnancy [103].
They found that human renin expression increased late in gestation and was detectable both in
chorionic trophoblasts and the maternal circulation of the pregnant transgenic mice. Several
other mouse models [105-109] draw similar conclusions as they explore the effects AT1
receptor signaling in the development of hypertension and end-organ damage in the heart,
vasculature and kidney. Our group has also investigated the timing of renin gene expression
during pregnancy using two different mouse strains, ICR and C57Bl/6. ICR mice exhibited
high levels of renin expression at the maternal-fetal interface [102]. In C57Bl/6 pregnant mice,
little placental expression of renin was observed, however the gene was upregulated in kidneys.
Both ICR and C57Bl/6 mice demonstrated an increase in circulating maternal renin during
gestation, however the sites of renin production differed. These animal models illustrate the
importance of RAS regulation in order to sustain a healthy pregnancy. Taken together, the
several animal models exploring RAS regulation in pregnancy suggest that these factors could
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play an important role in the pathogenesis of gestational hypertensive disorders. While these
animal models suggest that RAS dysregulation in pregnancy can lead to hypertension, they
cannot adequately address the specific scenario of PE. In this disorder, while the end effects of
AT1 receptor signaling, such as vasoconstriction, appear to be increased, the components of the
RAS, such as renin and ANG II, are not (Table 1). This puzzle implies that another factor must
be responsible for the excessive AT1 receptor activation observed in women with PE. The
aforementioned autoantibody, AT1-AA, which is found in the circulation of preeclamptic
women, may be responsible for this stimulation. Though many in vitro studies imply that AT1AA can induce the many biologic responses relevant to PE, such as increased cardiomyocyte
contractility and sFlt-1 secretion [33, 110], they cannot authoritatively label this autoantibody
as a major pathogenic player. In order to definitively show this autoantibody is a causative
agent of PE, an adoptive transfer experiment of AT1-AA in pregnant mice must be performed.

Chapter overview

This Chapter will report that when AT1-AA purified from preeclamptic women was
injected into pregnant mice, they recapitulate the key maternal symptoms: hypertension,
proteinuria and increased circulating sFlt-1 and sEng. Human IgG derived from healthy
normotensive pregnant women did not induce preeclamptic features when injected into dams.
In order to demonstrate autoantibody specificity, a short antibody-neutralizing epitope peptide,
7-aa, was co-injected in dams and decreased autoantibody-mediated effects. Losartan, an AT1
receptor blocker, also attenuated AT1-AA-induced features. The results of the adoptive transfer
mouse model reveal that the autoantibody found in preeclamptic women may contribute to the
pathophysiology of maternal disease features through excessive AT1-receptor activation.
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RESULTS

Human IgG is detectable in the circulation of pregnant mice.
To evaluate the pathophysiologic consequences of AT1–AA in vivo, purified total IgG
from either normotensive (NT) or preeclamptic
pregnant women was introduced into pregnant mice
on embryonic day (E) 13 and E14 by retro-orbital
injection. Western blot analysis indicated that human
IgG (hIgG) was readily detected in the injected mice
five days post-injection (Fig. 3a). To confirm these
findings, an ELISA was employed to quantify the
hIgG in mouse circulation. The ELISA results
indicated that concentrations in injected pregnant
mice were similar, whether injected with hIgG
derived from NT pregnant women or preeclamptic

patients (Fig. 3b). Finally, to determine if the
injected IgG retained biologic activity, when mice
were sacrificed on E18, IgG was purified from
maternal mouse sera, and assayed for the ability to
activate AT1 receptors in a luciferase reporter cell
line. These results (Fig. 3c) confirmed that hIgG
from preeclamptic women retained their ability to

Figure 3: Human IgG is detectable in
mouse sera. Human IgG (hIgG) injected into
mice were detectable in their sera 5 days postinjection by (a) western blot, ms; mouse sera
without injection (negative control), hIgG
(positive control); (b) ELISA *P<0.05 vs 2
day NT-IgG, **P<0.05 vs 2 day PE-IgG, and
(c) a luciferase-based bioassay reflecting
AT1-AA bioactivity on E18. *P<0.01 vs NTIgG. **P<0.05 vs PE-IgG. Data displayed as
the mean ± SEM, n=3 for each variable.
©Zhou et al., 2008. Originally published in
Nat Med. doi: 10.1038/nm.1856.
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activate AT1 receptors at least five days post-retro-orbital injection into pregnant mice. This is
contrast to the hIgG isolated from pregnant mice injected with IgG from NT pregnant women,
which could not stimulate AT1 receptor driven luciferase activity. These results verify that it is
possible to adoptively transfer physiologically relevant concentrations of hIgG into pregnant
mice, and that the biologically active injected human antibody persists for many days in the
maternal mouse circulation.

The adoptive transfer of IgG from preeclamptic women into pregnant mice leads to
hypertension and proteinuria through AT1 receptor activation.
Hypertension and proteinuria are the two
clinical

characteristics

defining

the

maternal

syndrome of PE. To determine if AT1-AA have the
ability to contribute to gestational hypertension,
systolic blood pressure of pregnant mice was
measured daily following the retro-orbital injection
of IgG purified from pregnant women. The
introduction of IgG from preeclamptic patients (PEIgG) but not IgG from normotensive pregnant
women (NT-IgG) resulted in a significant increase
in blood pressure that was evident four days postinjection (Fig. 2a). The increased blood pressure
Figure 4: PE-IgG induce a preeclampticlike state in pregnant mice. Injection of PEIgG into pregnant mice increases (a) systolic
blood pressure and (b) urinary protein.
*P<0.05 vs NT-IgG, **P<0.05 vs PE-IgG.
Data displayed as the mean ± SEM. ©Zhou et
al., 2008. Originally published in Nat Med.
doi: 10.1038/nm.1856.

resulting from injection of PE-IgG was prevented by
co-injection of losartan, an AT1 receptor antagonist
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(Fig. 2a). This suggests that the antibody-induced increase in blood pressure required activation
of the AT1 receptor.
The antibody-injected mice were also analyzed for proteinuria. After a 24h urine
collection using metabolic cages, the ratio of urinary albumin to creatinine on E18 was
examined. The results (Fig. 2b) show that a significant increase in urinary protein occurred
following injection of PE-IgG in contrast to injection of pregnant mice with NT-IgG. The
autoantibody-induced proteinuria was prevented by co-injection with losartan, indicating that
AT1 receptor activation was essential for this process. Overall, these results show, for the first
time, that IgG from preeclamptic women, in contrast to IgG derived from normotensive
pregnant women, are capable of inducing hypertension and proteinuria in pregnant mice, and
that these preeclamptic-like features required AT1 receptor activation.

Autoantibody-induced features of PE are prevented by co-injection of 7-aa.
AT1-AA interact with a specific seven amino acid sequence (AFHYESQ) present on the
second extracellular loop of the AT1 receptor [33]. Competition experiments indicated that this
epitope peptide is sufficient to block autoantibody-induced AT1 receptor activation [33, 111115]. In this regard, a short peptide of this sequence was generated (7-aa), to be routinely
employed as an autoantibody neutralizing agent. This is useful to determine if a particular
biological response (e.g. hypertension or proteinuria) can be specifically attributed to the
actions of AT1-AA. Thus, on E13 and E14, mice were co-injected with PE-IgG and 7-aa, and
then their blood pressure and proteinuria were monitored. These data (Fig. 2) show that coinjection with the 7-aa with PE-IgG successfully alleviated autoantibody-induced hypertension
and proteinuria. These findings imply that the hypertension and proteinuria resulted from IgG
37

derived from preeclamptic women which specifically binds to the second extracellular loop of
the AT1 receptor.

Affinity-purified AT1-AA and total IgG induce similar features upon injection into
pregnant mice.
To directly test the pathophysiological role of the autoantibody in PE, AT1-AA were
specifically isolated from total IgG derived from preeclamptic patients using an affinitypurification strategy. The ability of 7-aa to neutralize autoantibody-induced effects across
multiple cellular systems and previous studies [23, 33, 115, 116] suggests a physical
association between AT1-AA and the specific sequence, AFHYESQ, on the second
extracellular loop of AT1 receptor. Briefly, the strategy employed is as follows: a GST-peptide
fusion protein was generated containing the in frame insertion of a 27-amino acid DNA
sequence corresponding to the second extracellular loop of human AT1 receptor, herein named
GST-27-aa. After overexpression in bacteria and its subsequent isolation using glutathione
beads, the GST-27-aa was then coupled to affinity chromatography columns which were used
to specifically isolate AT1-AA from total IgG. The eluted fraction could bind to a 43kDa band
corresponding to AT1 receptors bound to a membrane by western blot analysis (Fig. 5a). In
addition, using the previously mentioned luciferase-based bioassay, it was confirmed that the
affinity-purified AT1-AA were capable of recognizing and activating the AT1 receptor (Fig.
5b). Only the eluted fraction (affinity-purified AT1-AA) was capable of inducing expression of
the luciferase reporter gene via AT1 receptor activation. The flow-through component was
unable to generate luciferase activity or recognize the 43 kDa band upon western blot analysis.
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These two facts indicate that the IgG fraction eluted from the affinity chromatography columns
contains IgG which bind to the second extracellular loop of the AT1 receptor.
Upon the confirmation
of retained biologic capability,
the affinity-purified AT1-AA
were injected into pregnant
mice. The introduction of the
affinity-purified

AT1-AA

resulted in a robust increase of
blood pressure apparent within
three days post-injection (Fig.
5c). These dams also developed
significant
5d).

proteinuria

Consistent

with

(Fig.
the

findings of total IgG derived
from
Figure 5: Affinity-purified AT1-AA induce a preeclamptic-like
state in pregnant mice. Western blot analysis (a) depicts the ability of
affinity purified fractions to detect AT1 receptors (AT1 r’) at 43 kDa.
Cell lysates from AT1 r’-rich cells were bound to a membrane. A
commericial anti-AT1 r’ antibody (lane 1) detected the 43 kDa band as
did the eluted fraction (AT1–AA; lane 3). The flow-through fraction
(lane 2) could not. AT1-AA bioactivity (b) was assessed using a
luciferase assay. The eluted fraction (AT1-AA) greatly stimulated
luciferase activity. AT1-AA purified from total PE-IgG injected into
pregnant mice lead to increased (c) systolic blood pressure and (d)
urinary protein. *P<0.05 vs NT-IgG, **P<0.05 vs PE-IgG. ©Zhou et
al., 2008. Originally published in Nat Med. doi: 10.1038/nm.1856.

preeclamptic

women,

hypertensive and proteinuria
induced

by

affinity-purified

AT1-AA were diminished by
losartan and 7-aa (Fig. 5c-d).
None of the mice injected with
control

IgG

displayed

preeclamptic-like features. These results provide direct evidence that women with PE harbor
autoantibodies which have an affinity for the second extracellular loop of the AT1 receptor and
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can be specifically isolated. Moreover, upon injection into pregnant mice activation of the AT1
receptor induces the symptoms of PE. The results of the affinity-purified AT1-AA also indicate
no statistically significant differences between the hypertension and proteinuria measured when
total PE-IgG was injected. This suggests that the total IgG houses a quantity of AT1-AA
sufficient to induce maximal blood pressure and proteinuria in pregnant mice.

Autoantibody-induced alterations in the mouse kidney.
Proteinuria is not the only renal dysfunction associated with PE. Characteristic
alterations in renal histology are also commonly observed. To evaluate the potential role of
AT1-AA in the renal pathophysiology of PE, the kidneys of pregnant mice injected with human
IgG derived from either NT or preeclamptic women were examined. On E18, five days postinjection, pregnant mice were sacrificed and their kidneys were isolated, fixed and sectioned.
Analysis of H&E stained sections from PE-IgG-injected pregnant revealed extensive renal
damage (Fig. 6a-b). The majority of their glomeruli were small and under high magnification,
endothelial swelling, narrowing or obliteration and occlusion of the glomerular capillary spaces

Figure 6: PE-IgG induced
renal damage in pregnant
mice. H&E staining (a & b)
reveals small, contracted and
consolidated glomeruli in
PE-IgG injected mice. Scale
bars (a) 200µm, 40X (b) 50
µm, 100X. PAS staining
(panel c) is unremarkable.
No PAS+ cells appear in the
glomeruli of any treatments.
©Zhou
et
al.,
2008.
Originally published in Nat
Med. doi: 10.1038/nm.1856.
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were evident, but showed no evidence of PAS-positive materials in the cytoplasm (Fig. 6c).
The affected glomeruli demonstrated the characteristic consolidated “bloodless” appearance, in
contrast to the open glomerular tufts of the pregnant mice injected with NT-IgG (Fig. 6). To
further confirm the AT1-AA-induced renal damage, mouse kidneys were stained using
Masson’s Trichrome for excess collagen deposition, as well as for increased complement factor
C3, by immunohistochemistry (Fig. 7). Elevated collagen (blue stain) was apparent in the
tubules of PE-IgG injected dams, but not in NT-IgG injected mice, and greatly diminished in
dams co-injected with PE-IgG and losartan or 7-aa (Fig 7b). The glomeruli of AT1-AA-injected
dams demonstrated increased positive complement C3 expression, whereas NT-IgG injected
pregnant mice did not (Fig. 7). Those mice co-injected with PE-IgG and losartan or 7-aa had
reduced C3 detected in their renal glomeruli. The increased deposition of collagen and
complement activation observed in the pregnant mice further illustrates the damage due to
autoantibody-mediated AT1 receptor activation.

Figure 7: PE-IgG increase
collagen and C3 deposition
in pregnant mice. Masson’s
trichrome staining (a) reveals
that increased collagen (blue)
is deposited in the tubules of
PE-IgG injected pregnant
mice. Immunohistochemistry
staining for C3 (a) indicates
C3
deposition
in
the
glomeruli of these mice
(arrows). Inset is another
glomeruli with C3 staining.
Scale bars 50 µm, 100X.
Quantification of Masson’s
Trichrome stain for collagen
(b) indicates an increased
blue density in the tubules of
PE-IgG injected pregnant
mice. *P<0.05 vs NT-IgG,
**P<0.05 vs PE-IgG.
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Examination of these kidneys by transmission electron microscopy (TEM) confirmed
the evidence of glomerular change by light microscopy. The endothelial cells of the affected
glomeruli demonstrated the loss of the fenestrations and because of their swollen cytoplasm,
lead to the narrowing or complete obliteration of capillary loop spaces (Fig 8). In addition,
focal foot process effacement was observed in the podocytes, as were the occasional electrondense materials in the mesangial and sub-endothelial areas. This collection of renal
histopathology is pathognomonic for the type of damage seen in kidneys of preeclamptic
patients. No significant mesangial cell proliferation or segmental glomerulosclerosis were seen
on light microscopy or TEM. The pregnant mice injected with NT-IgG were unremarkable and
did not show any of these histologic changes (Figs. 6-8). The histologic changes seen in the
kidneys of PE-IgG were partially prevented in mice co-injected with losartan or 7-aa and PEIgG (Figs. 6-8). Similar renal damage was consistently observed in pregnant mice injected with
affinity-purified AT1-AA. Taken together, these data imply that the autoantibody, through AT1
receptor activation, can induce renal histopathological changes in pregnant mice which may
lead to their renal impairment.
Figure 8: Ultrastructure of
kidneys in PE-IgG injected
mice. Features of glomerular
endotheliosis are revealed by
TEM analysis of PE-IgG
injected
mice.
Swollen
endothelial
cells
(thick
arrows) occlude capillary
spaces (*). Subendothelial
deposits are evident (thin
arrows). Capillary spaces
appear open in NT-IgG
injected animals. Boxes
highlight podocytes, which
remain unremarkable in all
cases. 1500X. ©Zhou et al.,
2008. Originally published in
Nat
Med.
doi:
10.1038/nm.1856.
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Autoantibody-mediated increases in placental-derived anti-angiogenic factors, sFlt-1 and
sEng in pregnant mice.
Recently, sFlt-1 and sEng have been brought to the forefront in the study of PE. The
anti-angiogenic factor sFlt-1 is a soluble form of the VEGF receptor that is elevated
significantly in the circulation of preeclamptic women [37, 117]. During pregnancy, sFlt-1 is
secreted by the placenta, and is thought to contribute to hypertension and proteinuria by
interfering with VEGF signaling [118]. Similarly, soluble endoglin (sEng), a soluble form of
the TGF-β receptor, is also secreted by the placenta and is elevated in preeclamptic women
[39]. To evaluate the potential contribution of AT1-AA to increased production of these two
factors in PE, pregnant mice were injected with IgG from NT pregnant women or women with
PE on E13 and E14, and the circulating levels of sFlt-1 and sEng were determined upon
sacrifice on E18. The results (Fig. 9) reveal that both sFlt-1 and sEng levels were significantly
greater in pregnant mice who received injections of PE-IgG in comparison to those who
received NT-IgG. The autoantibody-mediated inductions of sFlt-1 and sEng in pregnant mice
were inhibited by the co-injection of losartan or 7-aa. This indicates that the AT1-AA-mediated
liberation of the anti-angiogenic factors, sFlt-1 and sEng, required AT1 receptor activation.

Figure
9:
Increased
circulating anti-angiogenic
factors in PE-IgG injected
pregnant mice. Both sFlt-1
and sEng are increased in the
sera of pregnant mice
secondary to AT1 receptor
activation
by
the
autoantibody. *P<0.05 vs
NT-IgG, **P<0.05 vs PEIgG.. n=6 for each variable.
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The effect of AT1-AA in non-pregnant mice.
In the previous section, it was demonstrated that human IgG derived from preeclamptic
patients and not normotensive pregnant women could induce sFlt-1 production upon injection
into pregnant mice (Fig. 9), which could be specifically blocked by losartan or 7-aa. Thus, the
autoantibody-induced hypertension and proteinuria observed in pregnant mice could be the
result of excessive placenta-derived sFlt-1 action. However, it is possible that AT1-AA could
contribute to these features independent of excessive sFlt-1. To test this hypothesis, NT-IgG or
PE-IgG

were

introduced

into

non-

pregnant mice, and their blood pressure,
renal function and sFlt-1 levels were
monitored. In contrast to pregnant mice,
the concentration of sFlt-1 in nonpregnant mice injected with NT-IgG
remained very low, and most importantly,
was not increased by the injection of IgG
Figure 10: Non-pregnant mice do not liberate excess
sFlt-1 when injected with PE-IgG. While sFlt-1 is
increased in the circulation of pregnant mice due to AT1
receptor activation, non-pregnant animals do not show
elevated levels of the anti-angiogenic factor when
injected with the autoantibody. *P<0.05 vs NT-IgG,
**P<0.05 vs PE-IgG.n=6 for each variable. ©Zhou et
al., 2008. Originally published in Nat Med. doi:
10.1038/nm.1856.

purified from preeclamptic women (Fig.
10). Therefore, sFlt-1 cannot be induced
by

IgG

purified

from

preeclamptic

patients in non-pregnant mice.

The blood pressure of non-pregnant mice was then monitored. The results (Fig. 11a)
show that PE-IgG, in contrast to NT-IgG, stimulated an increase in blood pressure. PE-IgG
were capable of inducing a significant increase in blood pressure four days post-injection. Coinjection of either losartan or 7-aa specifically inhibited the autoantibody-mediated increase
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(Fig. 11a). Additionally, there was no significant difference in the maximal AT1-AA-induced
hypertension observed in pregnant mice (Fig. 4) and non-pregnant mice (Fig. 11), suggesting
that AT1-AA-mediated hypertension is not entirely sFlt-1-dependent.

Figure 11: Effects of PE-IgG in non-pregnant
mice. Blood pressure (a) was increased secondary to
AT1 receptor activation by the autoantibody in nonpregnant mice. However, these animals do not show
extensive renal damage. Only mild proteinuria (b) is
evident. H&E staining shows only mild glomerular
contraction (c) which is far less severe than that
observed in similarly injected pregnant mice.
*P<0.05 vs NT-IgG, **P<0.05 vs PE-IgG. ©Zhou et
al., 2008. Originally published in Nat Med. doi:
10.1038/nm.1856.

The urinary protein of antibody-injected non-pregnant mice was then measured. A
double injection of PE-IgG was required to induce a mild increase in urinary protein in nonpregnant mice (Fig. 11b). This slight autoantibody-induced proteinuria could be inhibited by
co-injection of losartan or 7-aa, suggesting that the proteinuria observed in non-pregnant mice
was mediated by AT1 receptor activation. However, the amount of urinary protein achieved
following autoantibody injection in pregnant mice was far greater, as compared to that achieved
in non-pregnant mice. Finally, analysis of H&E stained sections from non-pregnant mice
revealed only mild renal damage following injection of PE-IgG (Fig. 11c) in comparison to the
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severe renal damage observed in similarly treated pregnant mice (Fig. 6). The glomeruli of
mice injected with NT-IgG displayed no hypercellularity and were normal in size and shape
(Fig. 11c). In the non-pregnant mice double-injected with IgG from preeclamptic women,
though the majority of the glomeruli were normal to slightly reduced in size, the endothelial
swelling evident in pregnant mice was absent. The mild decrease in glomerular size, likely due
to mesangial cell contraction via AT1 receptor activation, was not as pronounced as that
observed in the pregnant animals. The glomeruli in the PE-IgG non-pregnant mice were not as
consolidated as those of their pregnant counterparts and their capillary lumens and glomerular
tufts appeared wide. Overall, non-pregnant mice injected with PE-IgG showed unsubstantial
changes in renal histopathology.
.
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DISCUSSION

To formally examine the role of AT1-AA in the pathophysiology of PE, an adoptive
transfer experiment was performed. This autoantibody was injected into pregnant mice, who
then recapitulated several key features of the disease: hypertension, proteinuria, renal
morphologic changes, and the increase of the anti-angiogenic factors sFlt-1 and sEng. In each
case the autoantibody-induced feature of PE could be prevented by the co-injection of losartan,
an AT1 receptor antagonist, or a 7-aa, autoantibody-neutralizing epitope peptide. Both total IgG
and affinity-purified AT1-AA induced similar symptoms in pregnant mice. Therefore, the
human IgG, affinity purification and autoantibody neutralization experiments provide direct
evidence supporting the claim that the features of PE observed in pregnant mice were induced
by an autoantibody which binds to and activates the second extracellular loop of the AT1
receptor. Though hypertension was detectable in non-pregnant animals injected with PE-IgG,
the other parameters, such as proteinuria, renal histologic changes and sFlt-1 production, did
not demonstrate clinically relevant increases. This implies that the observed autoantibodyinduced features are pregnancy-dependent. Overall, these findings confirm that AT1-AA
contributes to the pathophysiology of PE and raise the intriguing possibility that PE is an
autoimmune disease whose symptoms arise secondary to autoantibody-induced AT1 receptor
activation. Moreover, these in vivo studies offer direct evidence of the pathophysiological role
of AT1-AA in PE and provide an animal model to use as an investigative tool in the analysis of
the underlying pathogenic mechanisms associated with the disorder.
The two antiangiogenic soluble factors sFlt-1 and sEng are likely contributors to the
hypertension and maternal endothelial dysfunction associated with PE [37, 61, 69]. sFlt-1 is a
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placental-derived soluble form of the VEGF receptor-1 (VEGFR-1) which binds to and forms a
complex with free VEGF, thereby interfering with its signaling [118]. In the kidney, VEGF acts
to sustain glomerular fenestrations required for adequate filtration [119]. Therefore, diminished
VEGF signaling in glomeruli results in impaired renal function characterized by proteinuria and
often glomerular endotheliosis [117, 118, 120]. sEng is a soluble form of the TGF-β receptor,
endoglin, which complexes to free TGF-β and interferes with its signaling [39]. Both VEGF
and TGF-β increase the production of endothelial-derived nitric oxide (NO), a potent
vasodilator, resulting in vascular smooth muscle relaxation. In this way, sFlt-1 and sEng
enhance vasoconstriction in the peripheral circulation which manifests in hypertension. These
two factors are found to be elevated in the circulation of preeclamptic women, and cooperate
together to produce preeclamptic-like symptoms in pregnant rats [39]. However, the factors
accounting for increased production of sFlt-1 and sEng in preeclamptic women remain
undefined. From the data presented here, the autoantibody derived from women with PE may
be the instigating factor which stimulates sFlt-1 and sEng production through AT1 receptor
activation, and through this mechanism, may contribute the hypertension and proteinuria
observed in the disease.
Both AT1-AA and sFlt-1 can stimulate increased blood pressure. Therefore, it is
possible that their effects may be additive. However, both non-pregnant (Fig. 11) and pregnant
(Fig. 4) mice demonstrated similar maximal blood pressure readings of ~140 mmHg upon
autoantibody injection, despite the latter group harboring a considerably higher concentration
of circulating sFlt-1. A possible explanation for this is that the amount of AT1-AA injected into
mice (pregnant or non-pregnant) was sufficient to induce a maximal increase in blood pressure,
and though present in pregnant animals, the additional sFlt-1 was unable to stimulate an
additional increase. A similar phenomenon was recorded by Maynard et al. [118]. In
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experimentally manipulated rats, a low dose (7.3 ng/ml) of sFlt-1 was capable of inducing a
maximal blood pressure of ~120 mmHg. A 20-fold increase in the dose of sFlt-1 (>200 ng/ml)
was unable to further increase their systolic pressure [118]. This suggests that the capability of
sFlt-1 to elevate blood pressure is limited, and a maximal threshold for increase can be easily
reached. Based on the findings reported here and those of Maynard et al., AT1-AA and sFlt-1
can independently and additively contribute to the hypertension associated with PE.
In addition to its well-recognized role in regulating blood pressure, ANG II also induces
inflammation, vascular damage and proteinuria, through AT1 receptor activation. Ray et al.
have shown mesangial cell proliferation through this mechanism [121]. Others have shown
ANG II stimulates the production of PAI-1 by cultured endothelial cells [122, 123]. AT1
receptor activation has also been implicated in endothelial cell hypertrophy [124]. Excess ANG
II can induce renal damage leading to proteinuria in both wild-type rats [124] and transgenic
rats overexpressing human renin and angiotensinogen genes [125-128]. Since AT1-AA acts in
the place of ANG II, it could be expected to produce similar consequences. Previously, our
group has shown that IgG derived from women with PE stimulated mesangial cell production
of both PAI-1 and IL-6, a pro-inflammatory cytokine [113]. Therefore, AT1-AA may contribute
to renal histopathology by activating AT1 receptors on glomerular endothelial and mesangial
cells. It was shown here that introduction of AT1-AA into pregnant and non-pregnant mice
resulted in severe and mild renal dysfunction, respectively.
Renal damage was especially obvious in PE-IgG pregnant injected mice. Routine H&E
staining revealed contracted glomeruli with a consolidated appearance, endothelial cell
swelling and narrowed capillary lumens (Fig. 6). PAS staining indicated that there were no
PAS-positive deposits throughout glomerular cytoplasm nor was there increased mesangial
matrix observed in these mice (Fig. 6). When stained for excess collagen using Masson’s
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Trichrome, the PE-IgG injected dams showed elevated collagen in their tubules, but not
glomeruli, whereas NT-IgG injected mice did not demonstrate excess collagenous deposition
anywhere within their kidneys (Fig. 7). Though the extent of tubular damage in the human
disease is not well-characterized, there are several varied reports of tubular atrophy, fibrosis,
and collagen deposition, all of which could contribute to the proteinuria and renal dysfunction
observed in these women [129-132]. Renal tubules are considered especially responsive to
hypoxic changes and susceptible to injury, as the medulla has a lower oxygen content in
comparison to the cortex [133]. Pedrycz et al. observed superimposed PE in an experimental
model of nephrotic syndrome in rats who demonstrated considerable tubular dysmorphology
[134]. Moreover, ANG II is capable of stimulating collagen synthesis in vascular smooth
muscle cells [135] and glomerular mesangial cells [136], among others, which could contrible
to tubular injury. Since co-injection of the autoantibody with losartan or 7-aa reduced renal
tubular collagen deposition, AT1 receptor activation by the autoantibody may be responsible for
these changes in adoptively transferred mice, and could thereby contribute to similar features in
the human disease.
Complement, the bridge between innate and acquired immunity, becomes activated to
combat disease, or to remove immune complexes, ischemic or apoptotic cells [137, 138].
Activation of the complement cascade, in particular the converging component, C3, is a wellrecognized contributor to proteinuric renal dysfunction [139-142]. Complement activation is
reportedly increased in preeclamptic women, however, the factors leading to its induction
remain unknown [143-146]. Interestingly, Shagdarsuren et al. have recently demonstrated
using a double transgenic mouse model of RAS overexpression that ANG II mediates
complement activation and subsequent renal damage [128]. There are other reports to support
an AT1 receptor-induced mechanism of complement activation [126, 147]. It is therefore
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possible that the autoantibody, AT1-AA, could induce a similar immunologic response. Here, it
is shown that the glomeruli of PE-IgG injected pregnant mice demonstrate elevated C3
expression by immunohistochemistry (Fig. 7), whereas NT-IgG do not. Co-injection of losartan
or 7-aa with the autoantibody reduced C3 activation. The evidence of complement activation in
the kidneys of autoantibody injected pregnant mice is yet another clear indication that AT1-AA
may incite the renal damage associated with PE. The exact consequences of increased tubular
collagen deposition and glomerular C3 activity in autoantibody-injected mice are the subjects
of ongoing work in the lab.
Since non-pregnant animals did not display the same severity of renal damage (Fig. 11)
as their pregnant counterparts, another factor may additively contribute to this feature: it could
be that autoantibody-induced sFlt-1 in pregnant mice is the essential factor leading to the severe
renal damage observed. The injection of exogenous sFlt-1 into a rat results in renal lesions
similar to those observed in PE [118]. In pregnant mice, AT1-AA can induce sFlt-1 production
by the placenta, which could, therefore, be responsible for the renal changes recorded in these
animals. Furthermore, the renal dysfunction and the level of urinary protein achieved in
pregnant mice is much more severe than in non-pregnant mice, who demonstrate much lower
levels of sFlt-1. It is likely that in pregnant mice, AT1-AA-induced renal dysfunction may be
mediated through both the action of sFlt-1 and the direct effects of autoantibody-induced AT1
receptor activation on glomerular endothelial cells and/or mesangial cells. It could be that these
effects are independent or additive. Future work will have to delineate whether the renal
damage and proteinuria observed in the human disease is the result of sFlt-1 or AT1-AA action.
To test this, PE-IgG-injected pregnant mice could be co-injected with recombinant VEGF121, a
protein which blocks the anti-angiogenic action of sFlt-1 [148]. Certainly, from the evidence
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presented here, it appears that both AT1 receptor signaling and sFlt-1 are required to work in
tandem to produce the severe renal damage in PE-IgG injected mice.
The results of the adoptive transfer experiments presented here provide strong support
for the working hypothesis that PE is an autoimmune disease specific to pregnancy in which
AT1 receptor agonistic autoantibodies contribute to the development of many disease features.
Losartan, an AT1 receptor blocker, significantly reduces the key autoantibody-induced
symptoms in PE-IgG injected pregnant mice. This fact implies that the activation of this
receptor is specifically required as the mechanism of symptom progression. The biologic
properties of AT1-AA can also be attenuated by an autoantibody-neutralizing 7-aa peptide,
corresponding to the specific epitope located on the second extracellular loop of the AT1
receptor. This consistent control suggests a common immunologic origin for these
autoantibodies in different women, and has substantial therapeutic implications. Currently there
is no specific cure for PE, and severe cases often require the premature delivery of the infant. If
maternal circulating AT1-AA contributes to the pathophysiology of PE, as the adoptive transfer
model suggests, the timely removal or inhibition of these autoantibodies from preeclamptic
women may provide profound therapeutic benefit. Moreover, recent evidence suggests that
AT1-AA can be detected as early as 18 weeks, making it an early marker to identify women at
risk for the disease [149]. If AT1-AA play a significant role in the etiology of PE, as
hypothesized, it may be possible to block autoantibody-mediated AT1 receptor activation and in
turn forestall or prevent the onset of the preeclamptic symptoms.
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CHAPTER 4:

AT1-AA-INDUCED FETAL AND PLACENTAL ABNORMALITIES IN AN
ADOPTIVE TRANSFER MOUSE MODEL OF PREECLAMPSIA
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BACKGROUND

Two key features of PE were not discussed in the previous Chapter as they warrant their
own discussion: placental abnormalities and fetal consequences. Both placental dysfunction
and subsequent poor fetal outcomes are unfortunate features observed in the more severe cases
of PE. In this Chapter, I will explore the effect of AT1-AA on placentation and fetal outcome
using both the aforementioned adoptive transfer mouse model and culture systems of human
villous explants and a human trophoblast cell line. The data presented here will help broadly
demonstrate the pathogenic role of the autoantibody in PE, in particular its effects on the
placenta and fetus, and the essential need for improved therapeutics in the management of this
disorder affecting both mother and developing child.

Placental function and development during normal pregnancy
Good placental health is essential for an uncomplicated pregnancy. This complex organ
is the barrier between maternal and fetal cells, is a site of exchange for nutrients, oxygen and
waste products and is a producer of hormones [150, 151]. But the placenta has another
important function: it is an immunologic barrier. IgG may pass through the placenta from
mother to fetus via transcytosis and confer passive immunity [152-154]. Though there is some
controversy surrounding the rank of IgG subclasses which are actively transferred across the
placenta [155-157], most consider the efficiency in the order of IgG1>IgG3>IgG4>IgG2 [157,
158]. Of note, in a small study, Wallukat et al. report AT1-AA as sublass IgG3 [53].
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Humans and mice share similar features of their uteroplacental units. They are both
discoid chorioallantoic placentas and have hemochorial blood interfaces with three
corresponding physiologic and anatomically
distinct regions [159, 160]. In humans, on the
maternal side, the placental bed is made up of
the

decidua

basalis

and

the

underlying

myometrium. In mice, the corresponding area is
the decidua basalis only, and does not include
the myometrium [159]. The basal plate in
humans and the junctional zone in the mouse
are equivalent. They both produce hormones

Fig 12: Schematic of early mouse placental
structures. By E10, the labyrinth zone is wellestablished.

and cell lineages are primarily cytotrophoblastic [159]. In mice, there are cell types which are
not found in humans: spongiotrophoblasts (Mash2+), Trophoblast Giant Cells (TGCs; Hand1+,
Stra1+) and glycogen cells [161]. Closest to the fetus, the human placenta and the murine
labyrinth zone (LZ) are highly branched areas of maternal:fetal blood interface (Figs. 12-13)
[162]. There are 3 layers of fetal cells on the chorionic villi which prevent the mixture of
maternal

and

fetal

blood, yet allowing for
adequate

exchange

[162]. These zones are
made

up

of

syncytiotrophoblasts
(Gcm-1+) [159, 161].

Fig 13: Schematic of human chorionic villous blood interface. In this
diagram, the “middle section” is equivalent to the murine labyrinth zone.
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In humans, placental development begins towards the end of weeks gestational age 2
(WGA 2). By WGA 3, a primordial vascular network is apparent and a histiotropic-type
nutrition predominates [163, 164]. This source of nutrition for the fetus is derived from the
uterine glands which secrete nutrients. At this time, gas exchange relies entirely on diffusion
[165] and is, therefore, considered a time of relative hypoxia [165-167]. In order to establish
adequate blood-flow, endovascular trophoblasts invade the endothelial layer of the maternal
spiral arteries, leading to a hemochorial blood interface. The endothelial cells of the maternal
layer are entirely replaced by endovascular trophoblasts, resulting in the physiologic
transformation of the high resistance, muscular spiral arteries into low resistance, flaccid, wide
vessels [168, 169]. They become dilated 4-5 times to allow for increased uterine perfusion
[168]. Maximal trophoblast invasion occurs between WGA 7-9. By WGA 22, all invasion into
the placental bed is complete: all of the decidual and 75% of the myometrial spiral arteries are
now physiologically transformed [170-172].
In mice, implantation occurs on embryonic day (E) 4.5 [173]. By E8.0 the ectoplacental
cone is evident and there is abundant trophoblastic cell differentiation [173]. By E10.0, the LZ
is established as the placenta matures (Fig. 12). After E12.5, it is rare to have further cell
differentiation, but Gcm-1-mediated branching does occur in the LZ as the placenta increases in
size [162]. It should be noted that prior to E13, the TGCs are the most invasive cell type, but
>E13, glycogen cells take over that role [174, 175]. In the human, the analogous invasive cell is
predominately the invasive interstitial trophoblast cell [176, 177].
Whether in mouse or human, correct placentation is required for a healthy pregnancy.
Aberrant placental development may result in inadequate uteroplacental blood-flow and can
lead to detrimental sequelae in both mother and fetus, such as in the case of PE.
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Aberrant placental development in preeclampsia
As discussed above, the physiologic transformation brought about by the invasion of
trophoblasts into the endothelial lining of maternal spiral arteries is essential for sufficient
uterine blood-flow. However, in severe cases PE, placentas are often small, exhibit shallow
trophoblast invasion into the decidua and inadequate spiral artery remodeling, as well as
increased placental cell apoptosis [178, 179]. This insufficient placentation results in a
substantial reduction in uteroplacental blood-flow. In PE, it is has been long hypothesized that
it is this damaged placenta that liberates molecules, such as sFlt-1, which contribute to maternal
vascular injury and inflammatory responses [180]. The initiating mechanism for this damage
occurs has not been determined; though there is a mounting body of evidence implicating AT1AA, the autoantibody associated with PE.
AT1-AA may impair trophoblast invasion in PE through the increase of both sFlt-1 and
PAI-1. Zhou et al. have shown that AT1-AA induces the secretion of the anti-angiogenic factor
sFlt-1 in human placenta villous explants and human trophoblast cells [181], not to mention the
data presented in Chapter 1 which demonstrated that PE-IgG injected pregnant mice also have
elevated circulating sFlt-1 levels. This suggests that the autoantibody may contribute to the AT1
receptor-mediated sFlt-1 oversecretion in the placenta, endothelial cell dysregulation and
overly inhibited angiogenesis, which could result in impaired placentation. AT1-AA may also
induce the PAI-1-mediated placental damage observed in PE. By inhibiting urokinase-like
plasminogen activator (uPA), PAI-1 activity results in decreased conversion of plasminogen to
plasmin [75]. This leads to decreased fibrinolysis and extracellular matrix digestion, and
shallow trophoblast invasion, the hallmark placental lesion in PE. AT1-AA activates
trophoblast cells’ AT1 receptors resulting in elevated PAI-1 levels [21, 23]. Excess PAI-1 has
been shown in vitro to decreases trophoblast invasion using a matrigel assay [21, 22]. Thus,
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AT1-AA on human trophoblasts may contribute to increased PAI-1 production and lead to the
placental damage observed in PE. Collectively, AT1-AA-induced sFlt-1 and PAI-1 production
may additively contribute to the histopathologic changes observed in the placentas of
preeclamptic patients.

In PE, the changes in placental pathology are not without consequence. As previously
mentioned, placental health is vital in order to sustain an uncomplicated pregnancy. In the case
of PE, the small and underperfused placentas are thought to contribute to the poor fetal
outcomes associated with the disease.

Intrauterine growth restriction (IUGR)
Intrauterine growth restriction (IUGR) is defined as fetal growth less than the 10th
percentile for gestational age [182]. This complication of development affects ~15% of
pregnancies in the US annually [183, 184]. There are, however, more sequelae to IUGR than
simply being small; growth-restricted fetuses have a higher incidence of morbidity and
mortality than fetuses of average growth. They are also at increased risk for future development
of several metabolic disorders such as hypertension, dyslipidemia, coronary heart disease,
obesity, type 2 diabetes mellitus, impaired glucose tolerance [185-188]. Most cases of IUGR
are attributed to ischemic placental disease [184, 189]. Though the mechanisms leading to the
placental distress resulting in IUGR remain largely unknown, they are essential to understand
in order to prevent this very serious complication of pregnancy.
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IUGR, PE and the dysregulation of the RAS
The effects on the fetus are often overlooked in the study of PE. Placental dysfunction
leading to the premature births of babies who suffer from IGUR is commonly observed in this
disorder [190, 191]. Exactly how the IUGR in PE occurs is largely undefined; however, the
RAS regulates many components which could contribute to these problems. In fact, there are
many examples of how the RAS may affect placentation and fetal development. For example,
in the placenta, ANG II decreases system A amino acid transporter activity through AT1
receptor activation. This decrease in amino acid supply is thought to contribute to IUGR [4].
Feto-placental gene expression and the changes in circulation which regulate fetal oxygenation,
maturation and health are also regulated by the RAS [192]. A double AT1 receptor knockout
mouse model demonstrates that AT1 receptors are essential to attain appropriate somatic growth
and normal kidney structure [193]. Saito, et al. and Furuya et al. expanded on the work of
Takimoto, et al. [103], and found that pups born to transgenic mice expressing human
angiotensinogen who had mated with males expressing human renin suffered from IUGR [104,
194]. These newborns were small and their thoracic and visceral organs were undersized,
suggesting that overexpression of RAS components may regulate fetal growth. These many
examples illustrate how alterations in the RAS may contribute to IUGR in the setting of PE.

A role for AT1-AA in preeclamptic IUGR
Based on the data presented in Chapter 3, where it was described that the introduction
of AT1-AA into pregnant mice resulted in the key maternal features of PE [38], I hypothesize
that the autoantibody may contribute to the placental and fetal features consistent with the
disease. Since the in vivo studies provided the first direct evidence of the pathophysiology
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induced by AT1-AA in PE, this animal model was employed to address the exact role of AT1AA in IUGR and its underlying mechanisms.

Chapter overiew
In this Chapter, it will be shown that AT1-AA exist both in the cord blood of
preeclamptic women and in the fetal circulation of pregnant mice injected with the
autoantibody. The fetuses borne to autoantibody-injected mice are small and have impaired
multiple organ development. These findings indicate that AT1-AA enter fetal mouse circulation
where they may impose a direct detrimental effect on fetal maturation. Additionally, AT1-AA
impair placental development by increasing apoptosis, resulting in smaller organs. The murine
results were corroborated with similar findings in human placental explants and in cultured
HTR-8 cells exposed to AT1-AA. These studies demonstrate that abnormal placentation may be
a secondary underlying mechanism for autoantibody-induced IUGR. Finally, AT1-AAmediated IUGR and placental damage were largely corrected by co-injection with either
losartan or 7-aa, suggesting that autoantibody-induced AT1 receptor activation was required.
Overall, this work reveals the possible contribution of AT1-AA to the development of IUGR, as
well as two underlying mechanisms for this process. These novel findings suggest that
exposure to AT1-AA in the womb will have negative effects on a developing fetus and
placenta, and identify these autoantibodies as potential therapeutic targets.
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RESULTS

AT1–AA can be physically and biologically detected in preeclamptic cord blood.
The placenta is a vascular organ
which brings maternal and fetal blood into
close proximity. This interaction facilitates
the nutrient and gas exchange essential for
appropriate

fetal

development

[159].

Uterine spiral arteries supply maternal
blood to the placenta and the fetus receives
oxygenated blood from the umbilical vein
housed in the umbilical cord. Therefore,
cord blood represents an easily accessible
source of fetal blood which can be
obtained at the time of parturition. To
Figure 14: AT1-AA passes through the human placenta
and retains biologic activity. Celluar lysate of CHO.AT1
cells was run on an SDS-PAGE gel then transferred to a
nitrocellulose membrane. AT1 r’ rich lanes were cut into strips
and probed with an anti-AT1 r’ control, or IgG purified from
maternal sera or cord blood of NT (n=6) or PE (n=6) women.
Only sera or cord blood-derived IgG from PE, but not NT,
pregnant women can detect the AT1 r’ by western blot (a). The
eluate fraction of affinity-purified total IgG from the cord
blood of PE women could also detect the 43kDa band of the
AT1 r’. The luciferase-based AT1-AA bioassay was employed
to detect biologic activity (b). IgGs derived from the cord
blood of PE women and the eluate fraction could stimulate
AT1 r’ activated luciferase. n=10 in each category. Data are
expressed as mean ± SEM. *P<0.01 vs NT-IgG. **P<0.01 vs
PE-IgG. +P<0.01 vs flow-through fraction. ©Irani et al.,
2009. Originally published in J Exp Med. doi:
10.1084/jem.20090872

determine if AT1-AA cross from the
maternal

circulation

into

the

fetus,

maternal and cord blood from NT pregnant
women

and

women

with

PE

were

obtained. Total IgG was isolated from
their sera and examined for the presence of
AT1-AA. Western blot results (Fig. 14a)
indicate that total IgG from maternal and
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cord sera of PE women detected a band of 43 kD, which corresponds to the AT1 receptor
protein derived from cellular lysates enriched with the receptor which were transferred to a
nitrocellulose membrane. In contrast, IgG from maternal and cord sera of NT pregnant women
did not cross-react with the protein at this molecular weight (Fig. 14a). To confirm this result,
an affinity chromatography was employed to specifically isolate AT1-AA from the cord blood
of fetuses from PE women. Only the eluted fraction (AT1-AA) could detect a band at 43 kDa,
corresponding to the AT1 receptor, whereas the flow-through fraction did not. These findings
suggest that specific IgG from PE women which bind to the AT1 receptor cross the placenta
and enter fetal circulation, where they can be physically detected.
To determine if the IgG which enter fetal circulation retain the biologic ability to
activate AT1 receptors, IgG isolated from cord blood were incubated with a reporter cell line in
which activation of the AT1 receptor results in increased luciferase reporter gene expression.
The results showed that luciferase activity was increased only when cells were incubated with
IgG isolated from preeclamptic cord blood (Fig. 14b). This activity was blocked by losartan
(100nM), an AT1 receptor antagonist, or the 7-aa peptide corresponding to the sequence on the
second extracellular loop of the AT1 receptor, and is the epitope of AT1-AA. Similarly in using
the fractions obtained in the affinity-purification experiment, only the fraction of IgG eluted
from the cord blood of babies born to preeclamptic women increased luciferase activity,
whereas the flow-through fraction from PE women or eluate from NT pregnant women could
not. Taken together, these findings suggest that biologically active AT1-AA from maternal
circulation cross the placenta and enter fetal circulation where are capable of activating AT1
receptors.
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Human AT1-AA cross the mouse placenta and enter fetal circulation.
To determine if human autoantibodies can cross the mouse placenta and enter into their
fetal circulation, the autoantibody-injected model of PE was used. Briefly, pregnant mice were
injected with total IgG from NT or PE pregnant women on E13 and E14. Upon sacrifice on
E18, sera were obtained from the dams and fetuses and examined for the presence of human
IgG by western blot and ELISA.

The results (Fig. 15a-b) showed that human IgG was

detectable in similar quantities in the sera of both the antibody-injected pregnant mice and their
pups. Next, it was essential to determine if the human-derived PE-IgG retained its AT1 receptor
agonistic activity after crossing the mouse placenta and entering pup circulation. To do so,
human IgG was isolated from mouse fetal circulation and assayed for its ability to activate AT1
receptors using the AT1 receptor activated luciferase reporter assay [34, 38]. The results
indicate that IgG isolated from fetal blood of PE-IgG injected pregnant mice retained AT1
receptor agonistic activity (Fig. 15c). This is in contrast to the fetuses of dams injected with
NT-IgG, which harbored IgGs unable to stimulate luciferase activity. These data suggest that
human AT1-AA from women with PE can cross the mouse placenta, enter fetal mouse
circulation and retain the biologic ability to activate AT1 receptors.

Figure 15: Human IgG passes through the mouse placenta and retains biologic activity. PE-IgG or NTIgG were injected into pregnant mice. Upon sacrifice, fetal blood was collected. Human IgG was identified
in pups of dams injected with either NT-IgG or PE-IgG, by (a) western blot, and (b) ELISA. The ELISA
revealed no statistically significant difference of human IgG concentration between either cohort of animals
(P=0.6139). IgG derived from the pups from PE-IgG injected dams were the only group which could
stimulate AT1 r’ activated luciferase a bioassay. n=10 in each category. Data are expressed as mean ± SEM.
*P<0.01 vs NT-IgG. **P<0.01 vs PE-IgG. hHC; human IgG heavy chain. hLC; human IgG light chain.
©Irani et al., 2009. Originally published in J Exp Med. doi: 10.1084/jem.20090872.
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Affinity-purified AT1-AA injected into pregnant mice result in small fetuses with
impaired organ development.
During the process of passive immunity, harmful autoantibodies may be conferred from
mother to her developing child. In the case of autoimmune diseases, a potentially harmful
autoantibody may enter fetal circulation and have a direct detrimental effect. This may be the
case in PE, where it was just demonstrated that biologically active AT1-AA cross the placenta
and enter the fetal bloodstream. To investigate the profile of harm brought to the fetus by the
autoantibody associated with PE, affinity-purified AT1-AA were injected into pregnant mice on
E13 and E14. The injected mice were examined on E18 for the clinical signs of PE and their
fetuses were inspected for abnormalities of gestational growth. The results (Fig. 16) show that
AT1-AA-injected mice bore fetuses of reduced weight (1.01±0.02 g) compared to dams injected
with NT-IgG (1.17±0.02 g). Co-injection of AT1-AA with either losartan or 7-aa restored fetal
weight to 1.119±0.01 g and 1.151±0.04 g, respectively.
Figure 16: AT1-AA reduces fetal
weight. PE-IgG or NT-IgG were
injected into pregnant mice. Their
pups were weighed upon sacrifice.
Pups of dams injected PE-IgG
were smaller and weighed less
than those born to NT-IgG
injected animals. NT fetusues,
n=80. PE fetusues, n=89. Data are
expressed as mean ± SEM.
*P<0.01 vs NT-IgG. ©Irani et al.,
2009. Originally published in J
Exp
Med.
doi:
10.1084/jem.20090872.

In addition to their reduced weight, the fetuses born to AT1-AA-injected mice exhibited
delayed renal and hepatic maturation. Histologic analysis of fetal kidneys revealed a narrowed
zone of nephrogenesis and a reduced number of glomeruli in the kidneys of fetuses born to
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affinity-purified AT1-AA-injected mice (Fig. 17a-c). These parameters are used to measure
renal development [195], and their reductions suggest that of these kidneys was retarded.

Figure 17: AT1-AA impairs fetal
organ development. The kidneys
of pups born to PE-IgG injected
mice display delayed maturation
(a-c). The zone of nephrogensis
(double-headed
arrow)
is
narrowed (b) and the number of
glomeruli (arrows) in these zones
are reduced (c), as comapared to
pups of NT-IgG injected mice.
Livers of these pups also show
developmental delay (d,e) as they
retain elevated megakaryocytes
(arrow). Scale bars, 50 µm. n=12
for each variable. Data are
expressed as mean ± SEM.
*P<0.01 vs NT-IgG. **P<0.05 vs
PE-IgG. ©Irani et al., 2009.
Originally published in J Exp
Med. doi: 10.1084/jem.20090872.

Similarly, the liver of pups born to AT1-AA-injected dams showed developmental
delay. During normal mouse gestation, the fetal liver is a major site of embryonic blood
production. With advancing gestational age, the number of megakaryocyte progenitor cells
begin to decrease, starting at E10 [196]. Our histologic analysis showed that the injection of
affinity-purified AT1-AA into pregnant mice is associated with an elevation of megakaryocytes
in the fetal mouse liver (Fig. 17d-e). The persistence of megakaryocytes in the developing liver
suggests a delay in typical organ maturation. Thus, the autoantibody-injection model of PE has
provided evidence in vivo that AT1-AA adversely affects fetal growth and organ development.
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Notably, both human and murine studies indicate that biologically active AT1-AA pass
through the placenta and enter fetal circulation. These findings indicate a previously
unrecognized underlying mechanism of the IUGR observed in PE: that AT1-AA may have
direct detrimental effects on fetal development.

AT1-AA increases placental damage in mice and human villous explants.
Placental health is essential for normal fetal development. To determine if an impaired
placenta is second potential underlying mechanism for AT1-AA-induced IUGR, the weight and
morphology of placentas in autoantibody-injected mice were analyzed. The placentas of AT1AA-injected pregnant mice were significantly smaller (0.0939±0.008 g) than those of NT-IgGinjected mice (0.1039±0.014 g), P<0.05. In addition, co-injection of AT1-AA with either
losartan or 7-aa restored placental weight to 0.0991±0.009 g and 0.1050±0.023 g, respectively.
To determine whether increased apoptosis is a potential cause of the small placentas
observed in AT1-AA-injected pregnant mice, histologic analysis and TUNEL staining for
apoptotic cells were performed. Placental weight reduction was accompanied with increased
apoptosis evident in the labyrinth zone of placentas from AT1-AA-injected mice (Fig. 18a-b).
In addition, western blot analysis of mouse placenta protein extracts indicated that Bax, a proapoptotic protein, was increased, and Bcl-2, an anti-apoptotic protein, was decreased (Fig. 18cd). Co-injection of AT1-AA with losartan or 7-aa significantly inhibited these features.
Therefore, increased apoptosis could contribute to the reduction of placental size in AT1-AAinjected pregnant mice. These findings also suggest that an impaired placenta may indirectly
contribute to AT1-AA-induced IUGR in this model.

66

Figure 18: AT1 receptor activation results in
increased apoptosis in mouse placentas. Placentas
of PE-IgG mice have elevated levels of TUNEL+
cells (green) in their LZ (a). DAPI+ cells (blue).
20X. Scale bar, 500µm. Quantified TUNEL index
(% TUNEL+/DAPI+ cells) confirms the assay (b).
n=12 placentas examined for each variable.
Western blot analysis shows AT1 r’ activation
results in elevated expression of Bax (c) and Bcl-2
(d). n=6 placentas examined for each variable. Data
are expressed as mean ± SEM. *P<0.01 vs NT-IgG.
**P<0.05 vs PE-IgG. ©Irani et al., 2009. Originally
published
in
J
Exp
Med.
doi:
10.1084/jem.20090872.

Because apoptosis was increased in PE-IgG injected mice, the level of complement
activity was also assessed. Complement factor C3 could be easily visualized in the placentas of
PE-IgG injected mice (Fig 19, brown stain), especially in their junctional and labyrinth zones
and around areas of calcification. This detectable level was qualitatively more evident in the

Figure 19: Complement activation is elevated in mouse
placentas via AT1-AA. The placentas of PE-IgG injected
mice display elevated C3 (brown) staining by
immunohistochemistry. Co-injection of losartan or 7-aa
decreases C3+ stain. Box, magnified C3+ stain. 40X. Scale
bar, 200µm. n=4 placentas examined for each variable.
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placentas of PE-IgG injected mice than in NT-IgG injected animals, and was reduced in those
co-injected with the autoantibody and losartan or 7-aa. Then, to ascertain the level of
angiogenesis in the placentas of adoptively-transferred dams, CD-31, an endothelial cell
marker, was stained for by immunohistochemistry. The immunoreactivity of this marker was
less prominent in the labyrinth zones of PE-IgG injected animals (Fig 20). Quantitative analysis
of the immunostaining confirmed this observation (Fig. 20b). Co-injection of losartan or 7-aa
with the autoantibody partially restored the level of detectable endothelial cells to that
measurable in NT-IgG injected mouse placentas. Together, the histologic evidence suggests
that AT1-AA is capable of inducing significant placental damage when injected into pregnant
mice.

Figure 20: Angiogenesis is decreased in the placentas of PE-IgG injected mice. CD-31, an endothelial cell
marker (brown), is less prominent in the labryinth zone of the placentas of PE-IgG-injected mice in comparison
to those injected with NT-IgG (a). Counterstain is methyl green. Inset box: Junctional (J) and Labryinth (L)
zone border. Blood vessels are not apparent in the junctional zone. n=4 placentas for each category. Scale bar:
50µm. Quantification of CD-31 confirms that the placentas of mice injected with PE-IgG are less densely
stained than those injected with NT-IgG (b). Co-injection of losartan or 7-aa restores CD-31 positive staining.
Mean scores are represented ± SEM. n=4 placentas for each category. * P<0.01 vs NT. **P<0.05 vs PE. ©Zhou
et al., 2000. Originally published in Circulation. doi: 10.1161/CIRCULATIONAHA.109.902890.
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To evaluate the pathophysiologic significance AT1-AA-induced placental damage in
humans, human placental villous explants were obtained and cultured with NT-IgG or IgG
derived from women with PE. Following incubation, the explants were embedded, sectioned
and placed on slides in order to perform TUNEL staining. The results (Fig. 21) demonstrate
that the presence of PE-IgG increased apoptosis in these explants. This autoantibody-induced
increase in apoptosis was partially inhibited by co-incubation with losartan or 7-aa. The
histologic evidence was corroborated with western blot analysis which indicated an increase in
Bax and decrease in Bcl-2 proteins (Fig. 21c-d). Similarly, co-treatment with losartan or the
autoantibody-neutralizing peptide partially abolished the PE-IgG-induced alterations in Bax
and Bcl-2 proteins. These studies demonstrate that AT1-AA are capable of increasing apoptosis
in human placental explants through AT1 receptor activation which may potentially contribute
to IUGR associated with PE.
Figure 21: AT1 receptor activation
increased apoptosis in human villous
explants. Cultured human placental
explants incubated with PE-IgG
demonstrate
elevated
levels
of
TUNEL+ cells (green), indicating
increased apoptosis (a). DAPI+ cells
(blue). 20X. Scale bar, 500µm.
Quantification of a TUNEL index (%
TUNEL+/DAPI+ cells) confirm the
assay results (b). Western blot analysis
reveals that AT1 r’ activation results in
elevated expression of Bax (c) and Bcl2 (d) in placental proteins. Coincubation with losartan or 7-aa restores
programmed cell death to a level similar
to that observed in explants incubated
with NT-IgG. Explants from 4 different
patients were cultured, and each
variable was examined 6 times per
placenta, n=24. Data are expressed as
mean ± SEM. *P<0.01 vs NT-IgG.
**P<0.05 vs PE-IgG. ©Irani et al.,
2009. ©Irani et al., 2009. Originally
published in J Exp Med. doi:
10.1084/jem.20090872.
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Apoptosis is induced in human trophoblasts via AT1 receptor activation.
Human trophoblast cells maintain the full machinery for cell death by apoptosis [197199] and they possess AT1 receptors [3, 200]. To elucidate the mechanism of cell death which
occurs in the placentas of preeclamptic women, the levels of programmed cell death in
trophoblasts exposed to either PE or NT-IgG were monitored. IgG purified from preeclamptic
patients induced apoptosis in an immortalized human trophoblast line, HTR-8/SVneo (Fig. 22).
This is in contrast to NT-IgG, which was incapable of raising the level of apoptosis assessed by
a TUNEL assay and an apoptotic index. These results suggest that excess AT1 receptor
activation can lead to cell death by apoptosis in human trophoblast cells. Consistent with the
findings in the mouse placenta and in human placental villous explants, AT1-AA-mediated
increase in apoptosis in HTR-8/SVneo cells was inhibited by co-incubation with losartan or 7aa.

Figure 22: AT1-AA induces trophoblast
cell apoptosis. HTR-8/SVneo cells,
cultured with PE-IgG demonstrate higher
levels of TUNEL+ cells (green),
indicating increased apoptosis (a-b) than
do HTR-8 cells incubated with NT-IgG.
DAPI+ cells (blue). 20X. Scale bar,
500µm. Caspase 3 activity is increased (c)
in the PE-IgG treated cells. Co-incubation
with losartan or 7-aa decreases
programmed cell death and Caspase 3
activity to a level similar to that observed
in cells exposed to NT-IgG. n=12 for
each variable. Data are expressed as mean
± SEM. *P<0.01 vs NT-IgG. **P<0.05
vs PE-IgG. ©Irani et al., 2009. Originally
published in J Exp Med. doi:
10.1084/jem.20090872.

To corroborate the TUNEL assay results the activity of Caspase 3 was measured in
cultured trophoblast cells exposed to AT1-AA. Caspase 3 is a rapidly activated cysteine
protease and an essential component of the apoptotic pathway. HTR-8/SVneo cells incubated
with PE-IgG exhibited a higher Caspase 3 activity level over those incubated with NT-IgG
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(Fig. 22c). Cultured trophoblast cells co-incubated with AT1-AA and losartan or 7-aa
significantly reduced Caspase 3 activity. This data supports the results obtained from the
human placental explants experiments which demonstrated increased apoptosis upon exposure
to the autoantibody. Overall, these findings provide strong in vitro evidence that the
autoantibodies purified from the sera of preeclamptic women are capable inducing the
programmed cell death of human trophoblast cells via excess AT1 receptor activation.

Neutralization of AT1-AA-mediated actions by losartan and 7-aa.
Lastly, to determine if AT1-AA have a direct pathogenic role in the upregulation of the
AT1 receptor in PE-associated IUGR, losartan, a specific AT1 receptor antagonist, was coinjected with purified AT1-AA into pregnant mice on E13 and E14. Upon co-injection with the
autoantibody, losartan was capable of attenuating the reduction in placental size and the AT1AA-induced placental apoptosis, as well as the increased expression of Bax and decreased
expression of Bcl-2 (Fig. 18). This strategy to reduce AT1 receptor activation by the
autoantibody also ameliorated the reduction in fetal weight and poor maturation of the fetal
kidneys and liver (Fig. 16). Taken together, these observations imply that the impaired fetal
growth and increased placental apoptosis in this model were mediated by AT1 receptor
activation. Because the neutralizing peptide, 7-aa, blocked the apoptosis induced by AT1-AA in
cultured human placental explants (Fig. 21), this peptide could also be effective in blocking the
placental apoptosis and IUGR observed in AT1-AA-injected pregnant mice. Therefore,
experiments were conducted in which pregnant mice were co-injected with AT1-AA and excess
7-aa on E13 and E14, which would block the ability of the autoantibody to activate AT1
receptors. On E18, the dams were sacrificed and their placentas and pups were collected. 7-aa
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decreased placental apoptosis and the alterations of apoptotic proteins, and improved the
reduced fetal weights and impaired organ development (Figs. 16-20). The specific neutralizing
effects of both losartan and 7-aa indicate that the autoantibody, through AT1 receptor
activation, contribute to the placental damage and IUGR associated with PE.

72

DISCUSSION

In this Chapter, I examine the capability of AT1-AA to induce the placental damage and
IUGR observed in PE. First, it was demonstrated that biologically active autoantibodies of
preeclamptic women can cross the human placenta and enter into fetal circulation. Then, to
examine the role of AT1-AA in the fetal features of the disorder, the adoptive transfer mouse
model of PE was employed. The fetuses of AT1-AA-injected dams were small in size and
showed delayed organ maturation, as compared to pups born to mice injected with IgG purified
from normotensive pregnant women. The placentas of these mice were of reduced weight and
demonstrated significant histopathologic changes, including apoptotic damage. Therefore, upon
injection into pregnant mice, AT1-AA may contribute to fetal growth restriction through two
previously unrecognized mechanisms: (i) directly, via crossing the mouse placenta and entering
fetal mouse circulation, and (ii) indirectly, via AT1-AA-induced placental damage.
Furthermore, autoantibody-induced fetal growth restriction and abnormal placentation were
largely prevented by either losartan or an antibody-neutralizing epitope peptide, indicating that
autoantibody-induced AT1 receptor activation was required. These studies thereby reveal the
detrimental role of AT1-AA in PE-associated IUGR, offer two underlying mechanisms for this
condition and suggest a novel preventative strategy. Though the significance of these findings
must still be explored, this discovery highlights the important role of AT1 receptor signaling in
fetal development.
Antibodies generated by the mother can cross the placenta and enter into fetal
circulation during the third trimester of pregnancy. The transfer of IgG from mother to her
developing fetus is called passive immunity, and is a naturally occurring process. While usually
73

of great benefit, passive immunity can put the growing fetus at risk if the mother harbors
autoantibodies which are harmful. A well-recognized example of this is in Graves’ disease. In
this autoimmune disorder, maternal autoantibodies activate the thyroid stimulating hormone
receptor and pass through the placenta and enter fetal circulation, resulting in hyperthyroidism
of the fetus and newborn [201]. Other autoimmune diseases, such as antiphospholipid
syndrome (APS), systemic lupus erythematosus (SLE) and Sjogren’s disease are also
associated with passively transferred pathogenic autoantibodies which can result in major
complications of pregnancy, like severe IUGR and fetal loss [202-205]. Because PE is also
associated with deleterious maternal autoantibodies, it is possible that they may be transferred
to the growing fetus and cause harm. Using the adoptive transfer model of PE, it is shown here
that AT1-AA are transported from maternal to fetal circulation where they can be physically
and biologically detected. This implies that once the autoantibody reaches fetal circulation, it is
free to bind directly with fetal cells possessing AT1 receptors. In fact, the presence of the
autoantibodies in fetal mouse circulation results in excess AT1 receptor activation leading to
smaller sized animals who suffer from renal and hepatic abnormalities. Thus, AT1-AA may
also have detrimental effects on the fetuses born to women suffering from PE.
An impaired placenta may be another underlying mechanism responsible for AT1-AAmediated IUGR in PE. When the autoantibody is injected into pregnant mice, their placentas
are significantly smaller than normal and demonstrate vascular disorganization and
calcifications, a sign of placental distress. Moreover, AT1-AA induce apoptosis in a cultured
human trophoblast cell line (HTR-8), cultured human villous explants, and the placentas of
AT1-AA-injected pregnant mice. Since AT1 receptor stimulation by ANG II is capable of
increasing cell death via pro-apoptotic pathways in both cardiac and renal systems [206, 207],
and trophoblasts house AT1 receptor as well as all apoptotic machinery [198, 208], it is not an
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unexpected finding that AT1-AA can induce placental cell death by excessive AT1 receptor
activation. Poor placental development is associated with a pro-apoptotic placental
environment that includes the increased production of Bax and decreased production of Bcl-2
[209], features also observed in the placentas of AT1-AA-injected pregnant mice. Taken
together, these results indicate that this autoantibody can lead to significant placental damage.
As previously mentioned, complement activation is increased in preeclamptic women
but the factors responsible for this induction remain unknown [143, 144]. Many groups have
reported that ANG II-mediated AT1 receptor stimulation leads to the activation of complement
and organ damage [126, 128, 147]. In the placenta, highly active C3 is associated with the
secretion of sFlt-1 and sEng, as well as the serious consequence of APS-induced fetal loss [203,
210]. Here, it is shown that the placentas of PE-IgG injected dams demonstrate elevated
apoptotic activity, and therefore, it is not unreasonable that complement activity is also
increased. Indeed, the placentas of these mice have elevated C3 activity in their junctional and
labyrinth zones (Fig 19). NT-IgG injected mice did not demonstrate such an immunologic
response in their placentas, and those mice injected with losartan or 7-aa displayed diminished
C3 deposition. These facts indicate that AT1 receptor activation by the autoantibody may
contribute to placental damage through increased complement activity, in a similar manner to
how it does in the kidney (see Chapter 3). The exact outcome of increased complement activity
in the placentas of PE-IgG injected dams is the subject of ongoing work in the lab. It is,
however, clear that the autoantibody induces heightened complement activation in the mouse
placenta, implying that its blockade may prove beneficial in repairing AT1-AA-induced
placental damage. Furthermore, autoantibody-induced AT1 receptor activation could contribute
to placental damage through several other means, via decreased angiogenesis [24] and
trophoblast invasion [76], or increased ROS production [211, 212] and thrombosis [21, 41]. To
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determine if angiogenesis was decreased in the placentas of PE-IgG injected dams, CD-31, an
endothelial cell marker, was stained for by immunohistochemistry. In these dams, the amount
of CD-31 staining, representing the amount of placental endothelial cells, was reduced (Fig 20,
brown stain). Dams co-injected with PE-IgG and losartan or 7-aa had CD-31 levels partially
restored to that of the NT-IgG injected pregnant mice, suggesting the decrease in angiogenesis
was mediated by AT1-AA. Taken together, the autoantibody-induced increased cellular
disorganization, calcification, apoptosis and complement activity, as well as decreased
angiogenesis evident in the placentas of adoptively transferred mice indicate that AT1-AA may
contribute to similar features observed in the placentas of preeclamptic women.
These in vitro and in vivo studies support the findings of Takimoto et al. and Saito et al.
who discovered that the placentas of transgenic female mice expressing human
angiotensinogen which mated with males expressing human renin, are highly apoptotic and
their pups suffer from severe IUGR [103, 104]. These dams have increased circulating ANG II
and their placentas have increased renin levels. While these findings are significant, and have
been paralleled to PE, the human disease is not associated with greatly increased ANG II levels
[16] as in this double transgenic mouse model. However, human PE is associated with the
presence of autoantibodies, AT1-AA, which mimic the physiologic action of ANG II [33] and
could explain this observation. Therefore, the added stimulation of the AT1 receptor by the
autoantibody may contribute to impaired placental development and the IUGR associated with
PE. This hypothesis is supported by the work reported here and suggests that AT1 receptor
activation by the autoantibody is an underlying mechanism for the placental damage and the
IUGR observed.
It is a widely recognized that the maternal features of PE are secondary to placental
abnormalities, especially those stemming from placental ischemia [179, 213]. To investigate
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this concept, Granger et al. developed a rat model of PE wherein placental ischemia is
experimentally induced as a result of a surgical manipulation called reduced uterine perfusion
pressure (RUPP) [214-216]. This group examined the placentas and factors in the maternal
circulation of RUPP-treated rats with and found that sFlt-1 and inflammatory markers were
elevated [217]. The RUPP-manipulated pregnant rats also developed preeclamptic-like
syndrome including hypertension and proteinuria. Remarkably, these rats generated AT1-AA
[218], the same autoantibody found in the circulation of preeclamptic women. Consistent with
the presence of AT1-AA, when endothelial cells were cultured with the sera of RUPPmanipulated pregnant rats, endothelin-1 synthesis was increased by AT1 receptor activation
[216]. Endothelin-1 is a potent vasoconstrictor produced by endothelium which, in excess, can
contribute to hypertension [219]. In that regard, Granger and colleagues treated RUPP-induced
hypertension in two ways: using an antagonist to the AT1 receptor [217], or to the ETA
endothelin receptor [220]. Both of these strategies attenuated the hypertension in the surgically
manipulated pregnant rats, suggesting that RUPP-induced hypertension relies on AT1-AAmediated endothelin-1 synthesis. Collectively, these results indicate that autoantibody-induced
factors liberated by an ischemic placenta play an important role in the maternal symptoms of
PE [218].
The fetal abnormalities associated with PE most commonly occur in the severe earlyonset form of the disease [221]. The placentas of these women are characteristically small and
possess histopathologic evidence of ischemic change stemming from shallow trophoblast
invasion and inadequate remodeling of the spiral arteries [169, 189]. A possible mechanism for
the incomplete trophoblast invasion observed in PE is that a trophoblast population fails to
migrate to the spiral arteries due to excessive programmed cell death [222, 223]. I illustrate
here that autoantibodies present in the maternal circulation of women with PE can incite
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apoptotic damage in mouse placentas, human villous explants and HTR-8 cells. Together, these
results implicate a role for the autoantibody in the placental pathology associated with PE. This
hypothesis is supported by the work of Walther et al., who also suggest that these pathogenic
autoantibodies may contribute to the damage in the placentas of preeclamptic women when
they occur in early pregnancy [149]. These investigators found that AT1-AA were present by
18-22 weeks of gestation in women with impaired placental development as measured by
abnormalities on Doppler ultrasound [224]. When followed to term, approximately 20% of
these women developed PE, 20% developed IUGR without PE and 60% had an otherwise
unremarkable pregnancy. AT1-AA were not observed in women with a normal Doppler
ultrasound. Therefore, AT1-AA track with abnormal placental development, appear weeks
before maternal symptoms appear, and could serve to identify women at risk for IUGR and/or
PE. The authors of this study suggested, as our group had done earlier [23], that AT1-AA may
be responsible for the reduced trophoblast invasion and subsequent inadequate remodeling and
dilation of spiral arteries resulting in impaired placental vascular development. This lack of
vessel dilation could result in the hypoxic-ischemic damage detected in the placentas of
preeclamptic women, which may contribute to the IUGR observed in their fetuses.
AT1 receptor activation also regulates amino acid transport, whose reduction is another
mechanism associated with the small placentas and IUGR of severe PE. Amino acids supply
20-40% of the energy needed for fetal growth [225]. If amino acid transportation in the
placenta is impaired, the developing fetus may become nutritionally starved and at risk for
growth defects. Many amino acid transport systems are Na+-dependent and couple the
movement of Na+ into the cell with the uptake of amino acids. The Na+-K+-ATPase is an
amino acid transporter which is highly abundant in most cell types, including the
syncytiotrophoblasts of the placenta [226]. A syncytiotrophoblast maintains a low intracellular
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Na+ concentration by transporting the cation outside the cell. This creates a Na+ gradient, which
is the driving force for Na+-dependent amino acid transport systems. Recent studies have
shown that the Na+-K+-ATPase is downregulated in IUGR [227], and the inhibitory effect on
Na+-dependent amino acid transport systems is through AT1 receptor activation. Another study
by Shibata et al. reports that ANG II, through AT1 receptor signaling, inhibits system A amino
acid transporter activity in human placental villous fragments [4]. The system A amino acid
transporter is a Na+-dependent amino acid transporter which controls the movement of small
neutral amino acids (alanine, serine, glutamine and glycine) in syncytiotrophoblasts. This work
confirms that ANG II, via AT1 receptor signaling, decreases system A activity by suppressing
Na+-K+-ATPase activity in human placental villi. It is possible that other Na+-dependent amino
acid transport systems could also be inhibited by increased AT1 receptor activation. Shibata et
al. believe that their findings may account for the adverse affects of elevated AT1 receptor
activation on fetal growth. They specifically propose that one possible source of excess AT1
receptor activation in IUGR associated with PE is the presence of maternal AT1-AA. The work
reported here adds support to their theory.
Other examples of IUGR involve the harmful effects of autoantibodies at the maternalfetal interface, which often results in fetal loss. A well-characterized example of this is the
antiphospholipid syndrome (APS). APS is a devastating disorder of pregnancy characterized by
maternal thrombosis and recurrent fetal loss [228]. Recurrent fetal loss occurs in ~1% of
pregnancies and ~20% of these women harbor anti-phospholipid antibodies (aPL) [229]. By
injecting aPL into pregnant mice, Girardi et al. created a model of recurrent fetal demise. They
show that these autoantibodies target the decidua at the maternal-fetal interface and instigate
severe damage. Once bound to their epitope, aPL lead to the recruitment of neutrophils,
complement activation and the enhanced production of TNF-α, several anti-angiogenic factors,
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tissue factor, and ROS; all of which contribute to destruction of the decidua and fetal demise
[230]. It is important to note that these same features can be induced by AT1-AA in a variety of
systems [24, 211, 212]. Thus, these two models of autoantibody adoptive transfer (AT1-AA and
aPL) induce IUGR accompanied by severe placental damage. They both demonstrate that
immunologic factors, including those from innate and adaptive immunity, contribute to
pregnancy loss and IUGR. In both scenarios, the sequence of events resulting in fetal
complications is initiated by a deleterious maternal autoantibody. Together, AT1-AA and aPL
could additively account for one-third of IUGR and pregnancy loss cases [203]. In light of
these findings, the role of autoantibodies in other cases of IUGR, impaired placental
development and/or fetal loss warrants further investigation.

Autoantibody targeted therapies
In the work presented here, losartan and the 7-aa epitope peptide were used to assess the
specificity of AT1-AA-induced effects. Co-injection of the autoantibody with losartan, an AT1
receptor blocker, resulted in diminished placental damage and fetal abnormalities. Consistent
with the in vivo studies, apoptosis was reduced in human villous explants and trophoblast cell
culture systems incubated with losartan and AT1-AA. These results indicate that the observed
effects were mediated via AT1 receptor activation. Losartan is, however, contraindicated during
the first trimester of pregnancy because of its fetotoxic effects [231, 232]. In lieu of using this
AT1 receptor blocker, drugs aimed at the specific neutralization of AT1-AA would not be
expected to cause harm to the developing fetus. When AT1-AA was co-injected with the
autoantibody neutralizaing epitope peptide, 7-aa, improvements in placental and fetal health
were observed. This indicates that AT1-AA is specifically responsible for the induction of the
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AT1 receptor. Taken together, the ability of losartan and 7-aa to reduce the harmful effects of
AT1-AA provides additional evidence that this autoantibody contributes to the IUGR and
placental damage associated with PE. More importantly, the ability of 7-aa to neutralize AT1AA represents a potential preventative approach wherein blockade of autoantibody-mediated
AT1 receptor activation could reduce the incidence of IUGR associated with PE.

Impact and therapeutic implications
This study has great impact not only on the field of neonatology, but has far reaching
implications to many other fields of medicine and science. Together, IUGR and SGA affect
approximately 3% of all newborns and ~10% of those infants do not catch up in growth postnatally [233]. In general, those infants are at increased risk for future development of many
metabolic disorders such as hypertension, dyslipidemia, Syndrome X, coronary heart disease,
obesity, diabetes mellitus type II, impaired glucose tolerance [185-188, 234]. In the case of PE,
many long-term follow-up studies report that the infants born to women suffering from the
disease are at increased risk later in life for cardiovascular disease [235-237]. Therefore, this
autoantibody-injected animal model with be very useful in pre-clinical trials to address neonatal
issues, as well as the long-term study of the affected offspring. By identifying AT1-AA a
possible agent of IUGR and fetal maldevelopment, a wide range of therapeutic targets could be
developed to improve fetal growth and possibly stave off future medical repercussions. By
neutralizing the effects of the autoantibody-induced AT1-receptor activation early on in the
course of PE, physicians could not only improve the maternal symptoms, but also the
detrimental effects on the fetus.
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Conclusions
In conclusion, this study demonstrates that AT1-AA may contribute to IUGR in two
ways: directly, by activating AT1 receptors on multiple fetal organs, and indirectly, by inducing
placental damage (Fig. 23). Future work will have to delineate between the exact contributions
of each mechanism. However, this study clearly identifies AT1-AA as a detrimental factor
which plays a role in IUGR. Furthermore, the blockade of excessive autoantibody-induced AT1
receptor stimulation by losartan or 7-aa not only reduced the placental damaged observed in
both mice and humans, but also the fetal abnormalities seen in AT1-AA-injected mice. Thus,

Figure 23: Working model of AT1 receptor-mediated fetal and placental sequelae. AT1-AA, found
in maternal circulation, act (1) on the placenta to increase apoptosis and incite damage and (2) in the
fetus itself, causing direct harm. ©Irani et al., 2009. Originally published in J Exp Med. doi:
10.1084/jem.20090872.
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this work identifies a detrimental role of AT1-AA in PE-associated IUGR and reveals the
underlying mechanisms for this process. Selective neutralization of the autoantibody would
enhance physicians’ ability to forestall IUGR and minimize fetotoxicity. Therefore, targeting
AT1-AA is a potentially important therapeutic strategy for the treatment of PE and its
devastating fetal complications.
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CHAPTER 5:

THE ESSENTIAL ROLE OF AT1-AA-INDUCED TNF-α
IN A MOUSE MODEL OF PREECLAMPSIA
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BACKGROUND

An increased maternal inflammatory response is associated with PE and has been
speculated to contribute to the disease [238, 239]. A growing body of evidence supports the
claims that there is an increase in pro-inflammatory cytokines and chemokines in the
circulation of preeclamptic women [240, 241]. Some hypothesize that the activation of
leukocytes and upregulation of certain cytokines propagate a state of chronic inflammation in
some pregnant women which manifests in preeclamptic features [242, 243]. Increases in
circulating tumor necrosis factor-α (TNF-α), interferon-γ (IFNγ) and interleukin-2 (IL-2) in
preeclamptic women are well established [244-246]. In contrast, anti-inflammatory molecules,
such as IL-10 and IL-4 are reportedly decreased in these patients [247, 248]. This kind of proinflammatory cytokine profile could contribute to the maternal features of PE in a variety of
ways, such as inducing vascular and renal damage. However, what factors instigate this
heightened inflammatory response in PE are unknown and the exact contribution of proinflammatory cytokines to symptom development remains undefined.

Of all the inflammatory cytokines, TNF-α has been widely implicated in the
pathogenesis of PE. It is a potent cytokine with pleiotropic systemic effects [249] and is highly
conserved between mice and humans [250]. It predominately binds to the constitutively
expressed TNF-R1 in cells throughout the body in both species [251, 252]. In preeclamptic
women TNF-α is increased in the circulation [253, 254] and placental tissues [40, 245, 255].
Schipper et al. have shown that TNF-α drastically elevated in PE with fetal involvement. These
authors suggest that this increased production is related to impaired placentation [256].
Notably, when injected with low-dose exogenous TNF-α, pregnant rats develop the clinical
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symptoms of PE, such as hypertension and proteinuria. This experiment implies a central role
of this cytokine in the disease [217].

AT1 receptor activation has been implicated in the increase of TNF-α and other
inflammatory cytokines leading to organ damage in both cardiac and renal systems [206, 257259]. Therefore, it is possible that through this mechanism, the autoantibody associated with
PE, AT1-AA, may contribute to the increased inflammation which characterizes the disease and
instigate the vascular damage and systemic symptoms of preeclamptic women.

Chapter overview

Here, I explore if autoantibody-induced excess AT1 receptor activation is the
mechanism responsible for the increase in inflammation observed in preeclamptic women. I
employ the AT1-AA-injection pregnant mouse model, cultured human trophoblast cells and
human villous explants to investigate the contributory role of the increased inflammatory
response, specifically TNF-α, to disease symptoms and in the pathogenesis of PE. Moreover, I
identify a potential therapeutic strategy to decrease maternal symptoms by the blockade of
TNF-α action.
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RESULTS

An increased inflammatory state is induced in AT1-AA-injected pregnant mice.
A heightened inflammatory response is associated with PE and is hypothesized to
contribute to disease pathophysiology [238, 260]. To determine the role of AT1-AA in the
increased inflammatory response seen in PE, IgG purified from normotensive (NT-IgG) or
preeclamptic (PE-IgG) pregnant women was injected into pregnant mice at E13 and E14 as
previously described [38]. Upon sacrifice on E18, the sera of antibody-injected pregnant mice
were screened for the relative changes of a variety of cytokines using a sensitive multi-analyte
inflammatory cytokine ELISA (Fig. 24a). Injection of PE-IgG, in contrast to that derived from
normotensive pregnant women, resulted in a relative increase in pro-inflammatory cytokines
(such as TNF-α, IFN-γ and IL-6) and a decrease in anti-inflammatory cytokines (such IL-10),
which are similar to those changes reported in preeclamptic women [238, 241, 245, 261].

Circulating TNF-α is increased by AT1 receptor activation in autoantibody-injected
pregnant mice but not non-pregnant mice.
Among all the inflammatory molecules measured, TNF-α was the most elevated, and
was therefore the cytokine pursued (Fig. 24a, box). The observed relative increase of TNF-α in
autoantibody-injected pregnant mice was confirmed by quantifying its level using a
commercially available ELISA (Fig. 24b). PE-IgG increased serum TNF-α in pregnant mice, as
compared to NT-IgG (24.1±2.6 and 12.1±1.7 pg/ml, respectively). When PE-IgG was coinjected into pregnant mice with losartan, an AT1 receptor blocker, or 7-aa, an autoantibodyneutralizing epitope peptide, the autoantibody-mediated induction of TNF-α was specifically
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Figure 24: TNF-α regulaties the overall increased inflammatory response of AT1-AA-injected pregnant mice.
Pregnant mice were injected with PE-IgG or NT-IgG on E13 and E14. Upon sacrifice on E18, their serum was
screened for various cytokines using a sensitive assay. While NT-IgG injected mice have a predominantly antiinflammatory profile, PE-IgG injected mice have a pro-inflammatory response (a). TNF-α was the most elevated of all
the assayed molecules (box). Mice co-injected with AT1-AA and a TNF-α neutralizing antibody demonstrated
reductions in most pro-inflammatory cytokines. Further quantification (b) of serum TNF-α in these mice confirmed
that the cytokine was elevated in PE-IgG injected pregnant mice and not in NT-IgG injected pregnant mice. Coinjection of losartan or 7-aa resulted in decreased serum TNF-α levels in PE-IgG injected pregnant mice. Non-pregnant
animals injected with similarly purified human IgG fractions (white bars) did not demonstrate increased cytokine
levels. n=9 for each variable. Using the ELISA employed to quantify mouse serum TNF-α, a standard curve was
generated in the absence (control) or in the presence of two different doses of anti-TNF-α antibody (c). Using ANOVA
and Tukey’s post-hoc testing, there is no significant difference between the curves. *P< 0.05 vs NT. **P<0.05 vs PE.
Part b: ©Irani et al., 2010. Originally published in Hypertension. doi: 10.1161/HYPERTENSIONAHA.110.150540.
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inhibited. These results indicate AT1-AA, through activation of the AT1 receptor, could be
responsible for the upregulation of TNF-α in pregnant mice.
To determine whether TNF-α induction by AT1-AA in vivo is dependent upon
pregnancy, PE-IgG or NT-IgG were injected into non-pregnant mice (Fig. 24b). Autoantibodyinjected non-pregnant mice had lower levels of TNF-α than autoantibody-injected pregnant
mice (11.3±2.4 and 24.1±2.6 pg/ml, respectively), and the level of TNF-α was not significantly
higher in non-pregnant animals mice injected with either PE-IgG or NT-IgG (11.3±2.4 and
9.4±3.2 pg/ml, respectively). Thus, in contrast to what was observed in pregnant mice,
circulating TNF-α did not increase in autoantibody-injected non-pregnant mice.

TNF-α blockade in autoantibody-injected pregnant mice reduces overall inflammatory
response
To elucidate the critical role of TNF-α in the pathogenesis of PE, pregnant mice were
co-injected with IgG derived from preeclamptic women and a TNF-α neutralizing antibody. At
E18 the mice were sacrificed and their sera were collected for analysis using the multi-analyte
ELISA array. This array revealed an unexpected finding: that the neutralization of TNF-α
resulted in an increase in anti-inflammatory cytokines, such as IL-10, and a significant decrease
of inflammatory cytokines including IL-6, IFN-γ and TNF-α itself in the autoantibody-injected
pregnant mice (Fig. 24a). These results imply that TNF-α action is central to the recruitment of
other inflammatory cytokines and that neutralization of its actions reduces this effect. Then,
using a commercially available ELISA kit, it was quantitatively confirmed that the TNF-α
neutralizing antibody attenuated the induction of the cytokine in the serum of autoantibodyinjected pregnant mice (Fig. 24b).
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Furthermore, to determine if the ELISA kit used measured only free, unbound TNF-α,
or if it was capable of detecting the TNF-α bound to the anti-TNF-α antibody, a standard curve
for the cytokine was generated in the absence or presence of varying amounts of the TNF-α
blocker (0.0, 0.5 and 5.0 ng/ml) (Fig. 24c). The resultant curves showed no statistically
significant differences. This finding suggests that any reductions of TNF-α observed using this
ELISA are physiologic, and not due to interference of the neutralizing antibody.

Hypertension and proteinuria are reduced in AT1-AA-injected pregnant mice due to
TNF-α blockade
Because TNF-α is a key pro-inflammatory cytokine controlling the network of
inflammatory cytokines in autoantibody-injected pregnant mice, it is possible that neutralizing
TNF-α may also attenuate other maternal symptoms of PE observed in this model. The key
diagnostic features, hypertension and proteinuria, were both partially attenuated in animals coinjected with PE-IgG and a TNF-α blocker as compared to pregnant mice injected with PE-IgG
alone (Fig. 24). By E18, neutralization of TNF-α reduced hypertension from 132±4 to 110±4
mmHg and urinary protein 212±25 to 155±23 albumin (µg)/creatinine (mg) (both P<0.05).
Pregnant mice injected with NT-IgG retained their baseline blood pressure and normal renal
function, as did mice who were injected with the anti-TNF-α antibody alone. As a control, an
isotype IgG was co-injected into pregnant mice along with PE-IgG. The isotype IgG was
incapable of reducing the autoantibody-induced elevation in TNF-α. These findings provide
direct evidence of the essential role of TNF-α in maternal key features of PE seen in
autoantibody-injected pregnant mice.
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Figure 25.
TNF-α blockade
induced
reduces
AT1-AA
preeclamptic-like features. To
assess the pathophysiologic role
of TNF-α in autoantibody-induced
PE, hypertension and proteinuria
were monitored in pregnant mice
injected with PE-IgG, NT-IgG or
were co-injected with PE-IgG and
an anti-TNF-α antibody. The key
features of PE, hypertension (a)
and proteinuria (b), observed in
the PE-IgG-injected pregnant
mice were reduced with coinjection of the TNF-α blocker. In
addition, sFlt-1 (c) and sEng (d)
were also reduced by the TNF-α
blocker. As a control, an isotype
IgG to the TNF-α blocker was coinjected with PE-IgG and resulted
in none of the changes observed.
n=9 for each variable, except PE +
Isotype, n=6. * P<0.05 vs NT
**P<0.05 vs PE.

Increased TNF-α contributes to sFlt-1 and sEng induction in autoantibody-injected
pregnant mice.
Two soluble factors, sFlt-1 and sEng, are elevated in preeclamptic women and are
believed to contribute to hypertension and proteinuria [54, 61]. In Chapter 3, it was discussed
how sFlt-1 is elevated in the autoantibody-injection model of PE in the pregnant mouse [38].
To determine if TNF-α contributes to autoantibody-induced sFlt-1 and sEng, the circulating
concentration of both factors were assessed in antibody-injected animals. Injection of PE-IgG
increased the serum levels of sFlt-1 and sEng, and co-injection of with an anti-TNF-α antibody
significantly reduced the levels of sFlt-1 and sEng to values closer to those observed in mice
injected with NT-IgG (Figs. 25c-d). An isotype IgG to the TNF-α blocker was incapable of
achieving similar reductions, and when the anti-TNF-α antibody was injected into pregnant
mice alone the serum concentrations of these two factors remain unaltered. Therefore, AT1–
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AA-induced TNF-α may contribute to the increased production of anti-angiogenic factors in
this mouse model of PE, and that this induction may be attenuated by the presence of TNF-α
blocking antibodies.

Autoantibody-induced TNF-α contributes to the renal abnormalities associated with PE.
Renal abnormalities are commonly associated with PE in the human disease [262-264]
and these features are also seen in the antibody-injection model of PE in pregnant mice [38]. As
such, I used the animal model to investigate the contribution of TNF-α to these kidney defects.
Histologic evidence indicates that the glomeruli of PE-IgG-injected pregnant mice are smaller
and hypercellular as compared to those of mice injected with IgG from normotensive women,
whose glomeruli are open and easily distinguished (Fig. 26a). When AT1-AA was co-injected
with an antibody against TNF-α, the renal morphology was partially restored to normal. The

Figure 26. Autoantibody-induced renal damage is reduced by TNF-α blockade. Pregnant mice injected on E13
and E14 with NT-IgG, PE-IgG, or co-injected with PE-IgG and an anti-TNF-α antibody were sacrificed on E18. Their
kidneys were harvested and fixed for either routine H&E staining (a) or transmission electron microscopy (TEM) (b).
H&E staining demonstrates that the condensed, hypercellular glomeruli of the PE-IgG injected pregnant mouse are
partially restored in when co-injected with the autoantibody and the TNF-α blocker. 100X. TEM demonstrates that the
glomerular endotheliosis observed in the PE-IgG injected mice is reduced in the co-injected group. The kidneys of NTIgG injected mice or mice injected with the TNF-α blocker alone are unremarkable. 1500X, scale bar=10 µm. n=6 for
each variable. Box, intact podocytes. (*) capillary space. Thick arrow, endothelial cell nucleus. ©Irani et al., 2010.
Originally published in Hypertension. doi: 10.1161/HYPERTENSIONAHA.110.150540.
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glomeruli of mice injected with NT-Ig did not display any renal morphologic changes. The
light microscopy data was informative; however the hallmark renal lesion of PE, glomerular
endotheliosis, can only be confirmed by transmission electron microscopy (TEM). TEM
analysis indicates that this feature is present in autoantibody-injected mice (Fig. 26b). The
glomeruli of these mice show endothelial swelling resulting in the occlusion of capillary loop
spaces. Co-injection of autoantibody with an anti-TNF-α antibody partly restores the kidney
phenotype resulting in capillary spaces which are partially opened as compared to the glomeruli
of mice injected with NT-IgG, whose capillary spaces are wide and show no swelling or
obstruction.
To confirm that the histologic changes in the kidneys of the autoantibody-injected mice
were not secondary to the deposition of a human IgG complex, an immunofluorescence study
using an antibody against human IgG was performed (Fig. 27). Renal sections from human
kidney tissue involved by lupus nephritis, which are known to demonstrate IgG immune
complex deposition [265], were used as positive controls. The glomeruli of these patients show
granular staining for IgG in the glomerular basement membrane and the mesangium. Pregnant
mice injected with IgG purified either from NT or PE pregnant women did not demonstrate
staining consistent with immune complex deposition. This implies that the histologic changes
observed in the autoantibody-injected mice were not due to antibody-antigen complex
deposition in the kidney. Taken together, these findings illustrate that TNF-α is a downstream
signaling molecule of the AT1 receptor contributing to renal abnormalities associated with PE
and that TNF-α blockade may decrease the maternal renal symptoms associated with AT1-AAinduced PE.
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Figure 27: Injection of human IgG
into pregnant mice does not result
in
renal
immune
complex
deposition.
Immunofluoresence
using an anti-human IgG antibody
shows
no
immune
complex
deposition (FITC, green) in the
kidneys of pregnant mice injected
with human antibody derived from
either NT or PE pregnant women.
Co-injection of human IgG with a
TNF-α blocker, or the TNF-α
blocker alone also demonstrated no
deposits. A renal sections from
human lupus patients known to have
immune complex deposition were
used positive controls, n=2. All
other variables, n=4.

AT1-AA-induced placental abnormalities in pregnant mice are reduced by TNF-α
blockade.
Placental abnormalities are also associated with PE [266-268]. These features are also
observed in autoantibody-injected pregnant mice [38], and so it is therefore a convenient model
to evaluate the contribution of AT1-AA-induced TNF-α on the placental abnormalities
associated with PE. Pregnant mice were injected with PE-IgG or NT-IgG on E13 and E14 and
the injected mice were sacrificed five days later, at which time their placentas were isolated and
characterized. Routine H&E staining (Fig. 28a) demonstrated that the labyrinth zones of the
placentas of mice injected with IgG derived from preeclamptic women had placental
calcifications, a hallmark of placental distress, and centers of fibrinoid necrosis similar to that
of acute atherosis, a feature observed in human placentas from women with PE [269, 270]. The
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placentas of mice injected with IgG from normotensive pregnant women had undamaged
placentas free from calcifications and fibrinous centers. Notably, co-injection of pregnant mice
with PE-IgG and an anti-TNF-α antibody reduced the histopathologic changes observed in the
placentas of PE-IgG injected animals. These results indicate that AT1 receptor activation can
induce placental damage and that these changes can be reduced by blocking TNF-α action.

Figure 28. Autoantibody-induced placental damage can be reduced by TNF-α blockade. Pregnant mice were
injected with NT-IgG, PE-IgG, or co-injected with PE-IgG and a TNF-α blocking antibody. Their placentas were
assessed by H&E staining, 40X (a). PE-IgG injected mice had evidence of damaged placentas: calcifications (thin
arrow) and fibrotic areas (thick arrow). Their labyrinth zones appear heterogeneous and have abnormal pools of
blood (inset box). NT-IgG injected mice have unremarkable labyrinth zones and animals co-injected with PE-IgG
and the TNF-α blocker have reduced placental damage. Placental apoptosis was assessed by TUNEL staining (b).
10X. Scale bar, 1mm. PE-IgG injected mice had increased apoptosis in their labyrinth zones as compared to NTIgG injected animals. Quantification of the TUNEL assay (c) indicates a reduction in the TUNEL+ cells in
pregnant mice injected with co-injected with PE-IgG and a TNF-α blocker as compared to the PE-IgG alone. Mice
injected with the anti-TNF-α antibody alone had unremarkable placentas. n = 9 for each variable. Green; TUNEL+
cells. Blue; DAPI+ nuclei. Western blot densiometric analysis of placental protein extracts confirm the TUNEL
findings. Bax (d) was increased and Bcl-2 (e) was decreased in PE-IgG injected mice and partially restored in those
animals co-injected with the TNF-α blocker. n=6 for each variable. *P<0.05 vs NT. **P<0.05 vs PE. ©Irani et al.,
2010. Originally published in Hypertension. doi: 10.1161/HYPERTENSIONAHA.110.150540.
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Small placentas and fetuses are often associated with PE [169, 182, 189, 190].
Therefore, we assessed both of these parameters. Placental weights of AT1-AA-injected
pregnant mice were smaller (0.0921±0.017 g) than placentas from mice injected with NT-IgG
(0.1143±0.022 g). Co-injection of an anti-TNF-α antibody restored the autoantibody-induced
placental weight reductions to 0.0991 ± 0.042 g. In addition, the weight of fetuses born in litters
of 6-8 was analyzed. Autoantibody-injected mice bore fetuses of less weight (1.06±0.19 g) as
compared to dams injected with NT-IgG (1.24±0.06 g). Co-injecting AT1-AA with a TNF-α
blocker restored fetal size to 1.11±0.43 g. As compared to the NT-IgG-injected animals,
injection of the anti-TNF-α antibody alone had no statistically significant effect on placental or
fetal weight (0.1157±0.048 g and 1.27±0.10 g, respectively). Fetal and placental pairs: PE,
n=46; NT, n=53; PE + Anti-TNF-α, n=37; Anti-TNF-α alone, n=34. Overall, the autoantibody
induced reductions in placental and fetal weights were restored by co-injection of a TNF-α
blocker, implying an important role for this cytokine in the regulation of these effects.
Because TNF-α is a potent pro-apoptotic factor and increased placental apoptosis is
associated with PE [245, 253, 271], I investigated the level of apoptosis in the placenta of
autoantibody-injected pregnant mice. An increase in programmed cell death was observed in
the labyrinth zone of placentas from AT1-AA-injected mice as seen by quantified TUNEL
staining (Figs. 28b-c). This was further confirmed western blot analysis of Bax and Bcl-2, two
apoptotic regulatory proteins. An increase in Bax, a pro-apoptotic protein, and a decrease in
Bcl-2, an anti-apoptotic protein, were observed (Figs. 28d-e). The degree of apoptosis was
reduced in the placentas of mice co-injected with PE-IgG and the anti-TNF-α antibody. Mice
injected with IgG from normotensive pregnant women, did not show increased apoptosis. This
evidence confirms the fact that AT1 receptor activation can increase mouse placental damage
and TNF-α blockade can reduce these detrimental effects.
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A cohort of preeclamptic patients has increased TNF-α levels correlating to AT1-AA
bioactivity.
From the mouse work presented here, it has been established that AT1-AA contributes
to the induction of TNF-α in pregnant mice. To determine if a relationship exists between the
autoantibody and TNF-α in humans, serum levels of TNF-α was compared to AT1–AA
bioactivity in normotensive pregnant women (n=16) and women with PE (n=20). First, it was
confirmed that the preeclamptic population had increased serum TNF-α. Similar to other
reports [238, 241, 245, 253, 272], the results (Fig. 29a, Table 2) reflected that circulating TNFα is increased in preeclamptic patients, and its mean concentration was higher than that found
of normotensive pregnant women (48±3 and 16±3 pg/ml, respectively, P<0.001). Five of the
sixteen normotensive pregnant patients and none of the twenty preeclamptic women had
undetectable levels of the cytokine, which is also consistent with other studies [245, 272].
These findings confirm that serum TNF-α is increased in the cohort of preeclamptic women
studied here.
Figure 29: Circulating TNF-α
positively correlates to AT1-AA
bioactivity
in
preeclamptic
women. Preeclamptic patients
(n=20) used in the study
demonstrated an elevated level of
serum TNF-α (a). Normotensive
(NT) patients (n=16) did not
demonstrate elevated cytokine
levels, and 5 of 16 patients did not
have detectable levels. Solid line
indicates the median concentration.
The dotted line indicates the lowest
detectable threshold of the assay. A
positive correlation (b) between
AT1-AA bioactivity, as assessed by
an in vitro cell culture luciferase
reporter assay, and serum TNF-α
level in preeclamptic women was
identified (r=0.85, n=20, P<0.001).
©Irani et al., 2010. Originally
published in Hypertension. doi:
10.1161/HYPERTENSIONAHA.1
10.150540.
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Next, the bioactivity level of AT1-AA in the sera of women with PE and NT pregnant
women were determined by testing sera-derived purified IgGs for the ability to activate AT1
receptors using an established luciferase reporter gene system [38]. The purified IgGs isolated
from patient sera were incubated with a reporter cell line in which AT1 receptor activation
results in the stimulation of luciferase activity. Intriguingly, there was a positive correlation
between AT1-AA bioactivity and circulating TNF-α level in preeclamptic women (Fig. 29b,
r=0.85, n=20, P<0.001). These data confirm earlier reports that preeclamptic patients harbor
increased levels of AT1-AA and show for the first time that AT1-AA bioactivity is correlated to
serum TNF-α in preeclamptic women. Thus, it is possible that AT1-AA-mediated induction of
TNF-α may significantly contribute to the pathophysiology of the disorder in humans.

AT1 receptor-mediated TNF-α induction contributes to placental apoptosis and sFlt-1 and
sEng secretion in human villous explants.
Because no elevation of the cytokine was observed in non-pregnant animals injected
with the autoantibody, it is likely that the placenta contributes to the production of
autoantibody-induced TNF-α. As such, human placental villous explants were used to assess
the direct role of AT1-AA in TNF-α production in human. Placental explants incubated with
PE-IgG showed an increase in secreted TNF-α, whereas the cytokine was not induced in
explants incubated with NT-IgG (913.1±62.3 and 250.6±21.6 pg/ml, respectively) (Fig. 30a).
AT1 receptor activation was required for TNF-α secretion, as co-incubation of PE-IgG with
either losartan, an AT1 receptor blocker, or a 7-aa epitope peptide which neutralizes
autoantibody action, attenuated the induction of TNF-α levels (214.4±24.1 and 506.4±163.8
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pg/ml, respectively). Thus, IgG purified from women with PE is capable of inducing TNF-α
secretion via AT1 receptor activation from human placental villous explants.
To elucidate the pathophysiologic consequences of AT1-AA-induced TNF-α production
by the placenta, human placental explants and the explant culture medium were examined for

Figure 30: TNF-α blockade reduces AT1 receptor-mediated placental damage in human villous explants.
Culturing PE-IgG with human villous explants resulted in TNF-α secretion via AT1 receptor activation (a). Coculturing the explants with PE-IgG and losartan (5µM) or 7-aa (1µM) reduced the cytokine level, specifically
indicating that autoantibody-induced AT1-receptor activation was required. Incubation of the explants with NT-IgG
did not increase TNF-α secretion. Apoptosis was increased in explants incubated with AT1-AA and was partially
diminished by blocking TNF-α activity (b, c). Explants cultured with NT-IgG demonstrated decreased cell death.
TUNEL stained cultured human villous explants (b). Green; TUNEL+. Blue; DAPI+. 10X. Quantification of
TUNEL staining (c) indicates that co-incubation with PE-IgG and an anti-TNF-α agent (5µg/ml) reduces the
amount of apoptosis. Western blot densiometric analysis of explant proteins reflects an increase in Bax (d) and a
decrease in Bcl-2 (e). In addition, sFlt-1 (f) and sEng (g) secretion were reduced by co-incubation of PE-IgG with
an anti-TNF-α antibody. 6 different placentas were collected, and from each n=4, total n=24 for every variable.
*P<0.05 vs NT. ** P<0.05 vs PE. ©Irani et al., 2010. Originally published in Hypertension. doi:
10.1161/HYPERTENSIONAHA.110.150540.
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pathological changes associated with PE. Placental explants were incubated with IgG purified
from normotensive pregnant women and preeclamptic women in the presence or absence of a
TNF-α neutralizing antibody. The level of apoptosis was determined by a TUNEL assay
conducted on thin sections of fixed placental tissue. The results (Figs. 30b-c) show that
explants exposed to PE-IgG demonstrated an increase in placental apoptosis which was blocked
by the presence of a TNF-α blocking antibody. Placental fragments incubated with NT-IgG did
not show significant apoptosis. This evidence was corroborated with western blot analysis
indicating an increase in Bax and decrease in Bcl-2 proteins, resulting in a pro-apoptotic state
in these explants (Figs. 30d-e). These results suggest that autoantibody-induced placental cell
apoptosis is mediated through the action of TNF-α. Experiments were also conducted to
determine the role of TNF-α in autoantibody-mediated induction of the placental derived antiangiogenic factors, sFlt-1 and sEng. The results (Figs. 30f-g) show that the autoantibodymediated increases in sFlt-1 and sEng were reduced by TNF-α blockade. These findings are
consistent with those observed in the mouse model and suggest that AT1-AA-induced TNF-α
mediates sFlt-1 and sEng production.
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DISCUSSION

In this study, it was identified for the first time that an elevated TNF-α level is
correlated to AT1-AA bioactivity in preeclamptic women and provided both in vitro human
studies and in vivo mouse evidence that AT1-AA is a novel candidate directly inducing TNF-α
production via AT1 receptor activation. Neutralizing AT1-AA-mediated TNF-α induction
attenuates the increased placenta apoptosis and sFlt-1 and sEng secretion by cultured human
villous explants. Moreover, TNF-α blockade ameliorates all of the key features associated with
PE seen in autoantibody-injected pregnant mice in vivo. Both the mouse and human studies
reported here provide strong evidence that AT1 receptor activation by the autoantibody induces
TNF-α, and that the increased TNF-α production is an underlying mechanism contributing to
pathogenesis of the disease. Overall, these studies have identified the essential role of AT1-AAinduced TNF-α production in PE and demonstrated the importance of this cytokine in the
pathogenesis of the disorder. These findings suggest a novel therapeutic option for the
complicated management of this serious condition.
The increased maternal inflammatory response associated with PE is speculated to
contribute to the pathogenesis in the disease [247, 273]. However, the direct cause of the
increased inflammatory cytokine production is unknown and the pathogenic role of these
inflammatory cytokines is undetermined. Multiple in vitro studies demonstrate that increased
inflammatory cytokine production may lead to endothelial dysfunction, increased placenta
apoptosis, decreased angiogenesis and kidney abnormalities that are relevant to the
pathophysiology of the disease [242, 274, 275]. Because PE is a multisystem disorder, using
animal models to understand the cellular interplay is an essential step towards deciphering the
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specific signaling pathways involved. However, there are few animal models of PE available
and none of them have delineated the cause of the increased inflammatory response and its
pathogenic functions. Here, using a novel autoantibody-induced model of PE in pregnant mice,
it was shown that autoantibody-mediated AT1 receptor activation induces TNF-α, among other
inflammatory cytokines, and that its production through this mechanism is pregnancydependent. The results of this screen imply that the autoantibodies from preeclamptic women
are capable of inducing a pro-inflammatory response in pregnant mice. Since IgG purified from
normotensive pregnant women did not elicit the same cytokine profile, the effect can be
attributed to the autoantibody itself and not a non-specific immunologic response.
Next, it was demonstrated that TNF-α blockade attenuates autoantibody-induced
preeclamptic features in AT1-AA-injected pregnant mice, including hypertension and
proteinuria as well as reducing circulating TNF-α itself. Using an antibody competition
strategy, the evidence provided shows that the anti-TNF-α neutralizing antibody does not
interfere with the measurement of TNF-α concentration by the ELISA used in the study. Thus,
this finding indicates that anti-TNF-α antibody treatment decreases TNF-α induction in
autoantibody-injected pregnant mice. Using a multi-analyte inflammatory cytokine ELISA,
additional evidence shows that anti-TNF-α antibody treatment decreases other proinflammatory molecules observed in AT1-AA-injected mice. So, without interference, TNF-αinduced cell damage and inflammation create a detrimental cycle, facilitating further cell
damage and inflammation. However, in the presence of an anti-TNF-α antibody which
neutralizes TNF-α effects, this damage is decreased, slowing the malicious cycle and results in
blocking the heightened inflammatory network. Thus, it was revealed for the first time that
AT1-AA is a key mediator in inducing the inflammatory cascade in PE and that TNF-α
blockade can attenuate this response.
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The direct role of TNF-α in disease mechanism
Although a potential role of TNF-α induction in hypertension and proteinuria seen in PE
has been suggested, the pathogenic mechanisms underlying these effects have not been clearly
identified. Earlier studies have shown that the pro-inflammatory TNF-α, a 51 kDa
homotrimeric protein in its soluble form, is associated with both vascular damage and
hypertension [276]. Jovinge et al. have shown that mice deficient in TNF-α have reduced
atherosclerotic lesions, suggesting that the cytokine plays a key role in vascular injury [277].
Similarly, in salt-sensitive rats, TNF-α blockade has been successful in alleviating both the
hypertension and renal damage observed in this model [278]. In pregnant rats, TNF-α enhances
contraction and inhibits endothelial nitric oxide-cGMP-mediated relaxation in systemic vessels,
which could contribute to hypertension [279]. Chronic infusion of TNF-α into pregnant rats to
achieve a two-fold increase in concentration is sufficient to induce hypertension and increase
endothelin production, which the authors believe contributes to the vascular damage associated
with the maternal symptoms of PE [220]. These examples illustrate that the inflammatory
properties of TNF-α contribute to vascular damage and high blood pressure and could therefore
do the same in the situation of PE.
In addition, Muller et al. report a double transgenic rat model that has increased levels
of circulating ANG II which exhibits hypertension, renal dysfunction as well as increased TNFα [126]. In this model, the authors believe that increased TNF-α contributes to kidney injury via
complement activation and that excess ANG II sensitizes the vasculature to the effects of the
cytokine. The induction of TNF-α in the autoantibody-injection model of PE is accompanied
with an autoantibody-mediated increases in sFlt-1 and sEng. Others have also shown that sFlt-1
and sEng are induced by TNF-α [97, 280]. Thus, in view of the known hypertensive and renal
effects of sFlt-1 and sEng, it is possible that the hypertensive and renal effects of TNF-α are
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mediated through the increase of these soluble factors. The results of the animal model studies
reported here provide evidence to support the novel concept that autoantibody-mediated AT1
receptor activation induces TNF-α production which results in the maternal features of PE
including hypertension and proteinuria.
Besides the direct detrimental effects of TNF-α on maternal features, TNF-α has long
been implicated in the placental damage associated with PE [208, 209]. Though the nature of
placental damage is well-established in PE, the exact role and specific source of TNF-α remain
undefined. In this study, it was confirmed that TNF-α is increased in the serum of the
preeclamptic patient cohort studied, but also revealed that these elevated levels of TNF-α are
correlated to the AT1-AA bioactivity in these preeclamptic individuals. Using non-pregnant
mice it was demonstrated that AT1-AA-mediated TNF-α induction is pregnancy-dependent,
which implies that the placenta is a major source for increased TNF-α seen in circulation.
Supporting this mouse study, it was shown here that AT1-AA are also capable of inducing
TNF-α in cultured human villous explants. More importantly, both mouse and human studies
reveal the novel role of AT1-AA-mediated TNF-α induction in placental abnormalities seen in
PE including increased apoptosis, as well as sFlt-1 and sEng secretion. These findings are
supported by earlier studies showing that TNF-α is not only increased in the serum of
preeclamptic women, but also locally in the placenta where villous cytotrophoblasts express
TNF-receptor 1 (TNF-R1) and house all the machinery necessary to carry out programmed cell
death [198, 281]. Reister, et al. demonstrate that increased TNF-α generated by macrophages
found in the placentas of preeclamptic women leads to apoptosis in extravillous trophoblasts
[282]. More importantly, recent studies demonstrate that TNF-α directly induces the
detrimental anti-angiogenic factors, sFlt-1 and sEng, in cultured human villous explants [97,
280]. Overall, these studies are in agreement with the current findings and suggest an essential
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role of AT1-AA-induced TNF-α in both the maternal symptoms and placental features observed
in PE.

The indirect role of TNF-α in disease mechanisms
In other disease models it is unclear whether TNF-α has only a direct pathogenic role or
whether it contributes to disease features indirectly via the induction of other mediators. For
example, in rheumatoid arthritis, TNF-α induces the expression of other pro-inflammatory
cytokines, such as IL-1 which initiates a potent inflammatory cascade [283, 284]. Therefore, in
this situation, the blockade of TNF-α action decreases production of downstream mediators and
arthritic features are indirectly abrogated. As demonstrated by the inflammatory cytokine array
(Fig, 24), this may also be the case in PE.
It is clear through the evidence presented here that reducing TNF-α action significantly
attenuates the key preeclamptic symptoms initiated by AT1-AA in pregnant mice, indicating an
essential role for this cytokine in PE, be it directly or indirectly. In the placenta, decreasing
TNF-α production may directly reduce the amount of trophoblast apoptosis and result in a
healthier organ (Figs. 28, 30). By limiting placental damage, reductions in TNF-α may also
decrease the release of key anti-angiogenic factors, sFlt-1 and sEng (Fig. 30). With little
increase in these factors, the subsequent maternal vascular and renal damage may be reduced
thereby alleviating maternal symptoms. As described earlier, by decreasing circulating TNF-α,
other inflammatory mediators, such as IFN-γ, are also reduced. This leads to less TNF-α-driven
vascular injury via the initiation of inflammatory cascades. Should these pathways not be
instigated, then the endothelial damage associated with PE may not be as severe, and the
symptoms may be lessened. Together, these scenarios indicate that TNF-α may be directly or
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indirectly contributing to preeclamptic features and regardless, its blockade can reduce their
severity.
It should not be overlooked that AT1-AA alone may contribute directly to certain
features of PE which are independent of TNF-α. For example, the autoantibody can directly
stimulate the AT1 receptors of vascular smooth muscle cells and induce vasoconstriction [285,
286]. Likewise, the autoantibody could activate AT1 receptors on endothelial cells resulting in
the synthesis of endothelin-1, a powerful vasoconstrictive agent [219, 287]. The autoantibody
may also directly bind to AT1 receptors on renal mesangial cells to induce PAI-1 secretion [21].
Therefore, it is not surprising that TNF-α blockade only partially relieves autoantibody-induced
features of PE, including the partial attenuation of hypertension and proteinuria observed in the
pregnant mice co-injected with AT1-AA and the anti-TNF-α antibody (Fig. 25).

TNF-α and hypertension
In general, increased inflammation has been implicated in the pathogenesis of
cardiovascular injury and the development of hypertension. Immunosuppressed HIV+ patients
display hypertension upon aggressive anti-retroviral therapy which restores their depleted
cytokine-inducing CD4 T cell count [288]. Cancer patients infused with alloactivated T cells
which mount an inflammatory response also develop hypertension [289]. Reduced systemic
inflammation via thymectomy or pharmologic interventions decrease blood pressure in
genetically modified hypertensive rats [290-292]. More specifically, elevations in the proinflammatory cytokine TNF-α have been reported in patients with severe atherosclerosis [293],
congestive heart failure [294] and other forms of hypertension [295]. It has been proposed that
this pro-inflammatory cytokine plays a role in both the initiation and amplification of
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inflammatory cascades [296, 297]. The work reported here supports these claims, as it was
shown that TNF-α blockade can significantly reduce the circulating levels of other
inflammatory cytokines in PE-IgG pregnant mice (Fig. 24). There are many proposed
mechanisms by which TNF-α brings about vascular injury: by induction of other cytokines,
such as IL-6 [298], IL-1 [284]; increasing endothelin-1 [299, 300]; causing aberrant
angiogenesis [301] and the inhibition of endothelial-dependent release of nitric oxide and
vasodilation [302, 303]. All of these mechanisms reportedly contribute to systemic
inflammation and the subsequent hypertension observed in patients. Interestingly, many of
these same vascular injuries are observed in PE as well as other autoimmune diseases such as
rheumatoid arthritis, as well as through AT1 receptor activation [73, 304-307]. The mechanistic
relationship between hypertension, autoimmunity and inflammation is a topic of great interest
and will surely be the subject of exciting future work.
Several small-scale clinical trials have been performed to investigate the capability of
TNF-α blockade in the treatment of cardiovascular disease. Hurlimann et al. have demonstrated
that patients with rheumatoid arthritis receiving a TNF-α blocker have improved vascular
function and decreased progression towards atherosclerotic disease and hypertension over those
patients not receiving this drug [308]. Others have shown that anti-TNF-α treatment in
rheumatoid patients improves various cardiovascular outcomes, whereas untreated groups
suffer from a 5-fold increase in cardiovascular mortality [309, 310]. Fichtlscherer et al.
observed improved cardiovascular functional status in patients suffering from chronic heart
failure administered with a TNF-α blocker [311]. In addition, cardiovascular disease including
the incidence of PE is elevated in the case of SLE and rheumatoid arthritis [312, 313], implying
that autoimmune processes may play a role in the manifestations of disease symptoms.
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Together, these reports suggest that TNF-α plays a pivotal role in the inflammation associated
with hypertension, and reduction in its function may forestall symptom development.

Anti-TNF-α agents: a novel therapy for PE?
The current therapy for PE is extremely limited. There is no absolute cure for the
disorder. While physicians use anti-seizure medications to stave off severe ecclamptic
symptoms, delivery of the baby and placenta is the only way to abate progressing symptoms.
There is a dire need to improve the current therapy of this hypertensive complication which is
the indication for 15% of all preterm deliveries and 18% of all pregnancy-related deaths in the
US per year [29, 30, 178].
Based on the findings reported here, TNF-α blockade may be a possible therapy to
alleviate preeclamptic symptoms (Fig. 31). Similar to the effects of the anti-TNF-α antibody
employed in our AT1-AA-injected pregnant mice, a soluble TNF-α receptor also attenuates
hypertension seen in pregnant rats generated by a reduced uterine placental perfusion (RUPP)
[314]. Thus, both of these animal studies provide strong preclinical evidence to support the
novel therapeutic possibility of targeting this deleterious cytokine which is associated with PE.
Notably, both soluble TNF-α receptors and anti-TNF-α antibody therapies are used in many
autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
and inflammatory bowel disease [96, 315, 316]. Great success has been achieved by blocking
TNF-α activity in these diseases and is the mainstay of their treatment. Though there are
associated risks of infection with the available injectable proteins, the development of oral
small-molecule inhibitors is on the pharmacological horizon [283]. Thus, these soluble TNF-α
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receptor agents may prove to be safer, cheaper and require fewer doses, making them ideal for
use in the developing world where PE is extremely prevalent and deadly.

Therapeutic side effects
The reported side effects and known teratogenicity of a drug are extremely important
when considering its use in a pregnant woman. The US FDA currently classifies anti-TNF-α
agents as having no documented human fetal toxicity (Category B) [283]. Animal studies, such
as those of Giroir et al., have shown no evidence of teratogenicity in the pups born to mice
injected with an anti-TNF-α protein [317]. In addition, there is precedence for use of anti-TNFα agents in pregnant women. Roux et al. in their comprehensive review report several studies
where women being treated with anti-TNFα agents for various rheumatologic disorders have
successful normal gestations and births [318, 319]. This evidence of drug safety supports the
need for future work in employing anti-TNFα blockers in the management of PE.
While this dissertation did not follow the pups born to mice co-injected with AT1-AA
and the anti-TNF-α antibody, there were no adverse effects reported in the dams. Moreover, in
the pregnant mice injected with the anti-TNF-α antibody alone, there were no obvious harmful
consequences observed and these mice have blood pressure, renal function and placental
morphology similar to that of control mice injected with IgG derived from normotensive
pregnant women (Fig. 25). Based on these findings, the anti-TNF-α agent used do not cause
harm to the pregnant mice used in the adoptive transfer model. However, future studies will
have to be performed to ascertain any detrimental effects on the fetus.
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Figure 31: Schematic depicting the possible role of TNF-α in AT1-AA-induced preeclamptic features.
Autoantibody-mediated TNF-α signaling could generate the maternal symptoms associated with PE. This
implies that blockade of both TNF-α and AT1 receptor signaling may be potential therapeutic strategies in the
management of this serious disorder of pregnancy.

Taken together, these studies identified AT1-AA as a novel candidate responsible for
the increased inflammatory response associated with PE by directly inducing TNF-α production
via AT1-receptor activation (Fig. 31). Both human and mouse studies demonstrate that this
inflammatory cytokine plays an important role in the pathogenesis of this hypertensive
condition. Of significant importance, its blockade reduces the maternal features of the disease
in an adoptive transfer mouse model of PE. In addition, AT1-AA-induced placental damage can
be alleviated by preventing TNF-α action in human villous explants. These findings indicate a
central role of TNF-α in placental damage and subsequent disease symptom development. The
work reported here could be the foundation leading to future human trials and a possible
therapy for PE, a life-threatening disorder of pregnancy for which the current treatment is
extremely limited.
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GENERAL CONCLUSIONS & SIGNIFICANCE

Overall conclusions

Taken together, the body of work presented here makes a strong case that the
autoantibody, AT1-AA, plays a major role in the pathogenesis of PE. Many groups, including
our own, have shown that women with PE harbor increased levels of this autoantibody [33, 34].
In this dissertation, it was illustrated how biologically active AT1-AA can be purified from the
serum from preeclamptic patients and injected into pregnant mice. Upon injection with the
autoantibody, these dams recapitulate preeclamptic disease features: hypertension, proteinuria
and the liberation of detrimental anti-angiogenic factors [38]. Fetal and placental features were
also examined. It was established that autoantibody-mediated AT1 receptor activation
contributes to IUGR and placental abnormalities [99]. All of the disease traits observed, both
maternal and fetal, could be specifically reduced by the co-injection of an AT1 receptor blocker,
losartan, or an autoantibody-neutralizing peptide, 7-aa. Moreover, when human villous explants
were cultured in the presence of AT1-AA, increased liberation of sFlt-1, sEng and TNF-α were
recorded, as was elevated placental explant apoptosis. For most of the studies described,
parallel experiments were performed in non-pregnant mice in order to define the role of AT1AA independent of pregnancy. In general, the manifestation of autoantibody-mediated
preeclamptic symptoms required the state of pregnancy. These experiments demonstrate that
excess AT1 receptor activation by the autoantibody results in a preeclamptic-like state in the
pregnant mouse, and alongside the villous explant data, they demonstrate the pathogenic role of
AT1-AA in PE (Fig. 32).
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To further examine the mechanism by which the autoantibody may cause these
symptoms, the sera of PE-IgG-injected mice were examined for inflammatory cytokines.
Excess AT1 receptor activation resulted in the induction of several pro-inflammatory
molecules, most notably, TNF-α, a factor known to be increased in PE. Therefore, I employed
the adoptive transfer model to address the concept of TNF-α blockade in the disorder. Coinjection of AT1-AA and an anti-TNF-α antibody was capable of reducing disease features in
pregnant mice, including a heightened inflammatory response, and the liberation of detrimental
factors in cultured human villous explants. Therefore, these results indicate that AT1-AAmediated induction of excess TNF-α may contribute to preeclamptic symptoms.

Figure 32: The role of AT1-AA in preeclampsia. Excess AT1 receptor activation may contribute to both
the maternal and fetal features associated with PE.
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Through the work presented here, it can be concluded that the autoantibody, AT1-AA,
plays a pathogenic role in the hypertensive disease of pregnancy, preeclampsia. Both in vitro
and in vivo studies confirm that selective blockade of this autoantibody or its downstream
targets, such as TNF-α, alleviates the features associated with the disease. These facts have
immediate therapeutic implications which could improve upon the inadequate screening,
diagnostic markers, and treatments available for this prevalent and deadly disorder of mother
and child.

Other animal models elucidating the role of AT1-AA and the maternal features of PE
Our group is not the only to investigate the role of AT1-AA in the development of
gestational hypertension. To explore this concept, Dechend et al. mated female rats expressing
the human angiotensinogen gene with male transgenics expressing the human renin gene [320].
Towards the end of their pregnancy, these dams experienced hypertension and proteinuria
which resolved post-partum. These females developed other preeclamptic-like features, such as
glomerular fibrin deposition and placental vascular defects. Importantly, the same autoantibody
circulating in preeclamptic women, AT1-AA, was detectable in the serum of these pregnant
transgenic rats [320]. The remarkable finding of AT1-AA production in the setting of RAS
dysregulation implies that these features have a close relationship in the pathophysiology of PE.
Another group used a model of placental ischemia to elucidate the etiologic factors responsible
for the maternal syndrome. Granger et al. performed a surgical manipulation called reduction
uterine perfusion pressure (RUPP) in rats in order to determine if this reduced placental bloodflow could result in preeclamptic symptom manifestation [321]. Indeed, the RUPP-treated rats
experienced preeclamptic-like features: hypertension, proteinuria, and increased sFlt-1, TNF-α,
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endothelin production and endothelial dysfunction. Remarkably, AT1-AA could be isolated
from the manipulated rats, whereas un-manipulated pregnant rats did not produce the
autoantibody [218]. The same group investigated the effect of TNF-α infusion during
pregnancy. Again, hypertension developed and AT1-AA was detectable in the circulation of
pregnant rats infused with low-dose TNF-α throughout pregnancy [218]. Non-pregnant animals
did not share similar features, implying that adequate balance of inflammatory molecules and
placental perfusion are necessary for a healthy pregnancy, and that decreased perfusion may
lead to an inflammatory response triggering autoantibody production. The development of AT1AA in genetically and surgically manipulated rats as well as those infused with low-dose TNFα reveals the important relationship between RAS regulation and maternal health during
gestation. The consistent development of AT1-AA in these experimental animal models also
suggests a common antigenic origin, which provides evidence for the concept that PE is an
autoimmune disorder of pregnancy.

AT1-AA: prevalence, persistence and the push forward
The exact etiology of self-recognizing antibodies in autoimmune diseases is difficult to
discern. Many factors have been proposed which may lead to autoantibody production in
general, including genetic predispositions, maladaptive immune responses and environmental
triggers [322-324]. All of these mechanisms could contribute to the generation of the
autoantibody associated with PE. It is currently unknown what triggers the production of AT1AA and when the autoantibody first arises in pregnancy. In their original paper, Wallukat et al.
used affinity purification and peptide competition experiments to illustrate that the
autoantibodies found circulating in preeclamptic women have a common epitope: a seven
amino acid sequence on the second extracellular loop of the AT1 receptor (AFHYESQ) [33]. In
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another human study, we have shown >95% of 37 preeclamptic women harbored AT1-AA and
that the bioactivity of the autoantibody correlated significantly to disease severity, in particular
proteinuria [34]. Normotensive pregnant women were also assessed for the presence of AT1AA. Less than 30% of these women had any detectable autoantibody levels, which were fivefold less than those observed in the preeclamptic group. The consistencies of these studies
suggest a common immunologic origin of AT1-AA in preeclamptic women, an area of exciting
future work.
In the short term, preeclamptic symptoms usually abate within 48 hours postpartum and
normal blood pressure is restored approximately 12 weeks after delivery. However, a definitive
timeline of AT1-AA persistence in preeclamptic women is currently unknown. In a small study,
Hubel, et al. reported that 17.2% of 29 women with a previous history of PE harbored AT1-AA
18±9 months post-partum, versus 2.9% of 35 women without a previous history of the disorder
[325]. Future work will have to build upon this study to determine exactly when autoantibody
titers decrease post-partum in preeclamptic women.
The long-term cardiovascular and renal consequences of PE are areas of recent interest.
Many groups have reported that having a previous history of PE puts a woman at increased risk
for overall cardiovascular risk [326], stroke and chronic hypertension later in life [235, 327],
ischemic heart disease [328] and death due to cardiovascular complications [329], as compared
to women who have not suffered from the disorder. Renal complications may also persist in
preeclamptic women. Glomerular endothlelial cell swelling with fibrin deposition [330],
microalbuminuria and endothelial cell dysfunction [331, 332] have all been documented in
preeclamptic women several months post-partum. It will be of particular interest to determine if
AT1-AA are present in the women with a history of PE who go on to suffer from cardiovascular
and renal complications later in life.
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Taken together, the common immunologic features and long-term sequelae in these
human studies provide mounting evidence that PE may in fact be an autoimmune disorder of
pregnancy. Should this be the case, autoantibody-targeted therapies may be beneficial not only
in the immediate treatment of this devastating disease, but also to abate future health risks.
Further investigation into the natural history of these autoantibodies in preeclamptic women is
necessary.

Molecular mimicry: Human parvovirus B19 and the AT1 receptor
There are many theories as to how the process of autoimmunity occurs. Though none
have proven unequivocally true in all cases, there is one prevailing theory which may apply to
the generation of the autoantibody associated with PE: molecular mimicry. Molecular mimicry
involves an infection-induced activation of self-reactive lymphocytes. The generation of
autoreactive T and B cells results from sequence similarities between foreign peptides found on
bacteria or viruses and self-peptides found naturally throughout the body. There are many
examples of infectious agents causing autoimmune-induced pathology: β-hemolytic
streptococci

and

cardiomyocyte

antigen

similarities

resulting

in

rheumatic

fever;

coxsackieviruses leading to myocarditis; Trypanosoma cruzi infection followed by Chagas’
disease; Borrelia burgdorferi infection and Lyme disease arthritis [333, 334]. Importantly in
many cases, adoptive transfer experiments using animal models provide direct evidence that
infection with a particular pathogen results in its associated autoimmune disease [335].
As discussed earlier, AT1-AA, the autoantibody associated with PE, can be effectively
neutralized by a peptide corresponding to a short sequence on the second extracellular loop of
the AT1 receptor, AFHYESQ. This consistent association implies that this sequence may be the
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antigenic epitope to which the autoantibody is raised against. This fact begs the question, why
would a sequence found on a receptor located on virtually every cell type in the body be
autoreactive?
BLASTing AFHYESQ in the publically available protein sequence NCBI database
reveals a striking homology between this 7-aa sequence and the two capsid proteins, VP1 and
VP2, of the human parvovirus B19 (HPV B19). HPV B19 is a single-stranded DNA virus
commonly associated with hydrops fetalis, fetal anemia and childhood erythema infectiosum
[336]. 50-70% of adults are reportedly HPV B19 seropositive [337] and the persistence of
myocardial HPV B19 is associated with cardiomyopathies and endothelial cell dysfunction
[338, 339]. When comparing the sequences, there is 100% homology between that found in the
human AT1 receptor (accession number: EAW78905) and the VP1/VP2 capsid proteins of HPV
B19 (accession number: ABX89697). The conservation between the epitope of AT1-AA and
HPV B19 capsid proteins raises the possibility that molecular mimicry may underlie the
autoimmune mechanism associated with PE.
This finding has been observed by others who have performed small retroactive studies
regarding remote HPV B19 infection, the autoantibody and the prevalence of PE. After the
examination of normotensive pregnant and preeclamptic women for the presence of anti-HPV
B19 antibodies and AT1-AA, Stephan et al. found that there was no strict correlation between
the factors [340]. Therefore, the authors propose that the generation of AT1-AA was
independent of epitope mimicry of HPV B19. This finding could be due to the confounding
high seroprevalence in the population, and the requirement of a yet unidentified agent.
The fact remains that HPV B19 is a very common infection in most adults and only 8%
of pregnancies are afflicted with the complication of PE [178]. It is possible that only a portion
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of HPV B19 seropositive women develop autoantibodies against the conserved region on the
AT1 receptor; therefore implying that HPV B19 infection cannot be the only parameter
resulting in this disease of pregnancy. Environment and a particular genetic background may
also contribute to the generation of the autoantibody and preeclamptic pathophysiology.
Immunization of mice with the VP1/VP2 capsid proteins may provide more direct evidence
supporting (or disproving) this provocative hypothesis. Indeed, this intriguing scenario raises
the possibility that the immunologic origin of AT1-AA could be secondary to a parvovirus B19
infection: an exciting area requiring further investigation.

Autoantibody-targeted therapeutics
In the work presented here, 7-aa successfully attenuated the autoantibody-induced
symptoms of PE in pregnant mice. Although these findings have tremendous implications, the
evaluation of the therapeutic potential of autoantibody-neutralizing peptides was not a focus of
this body of work. In the present study, the neutralization of AT1-AA by the 7-aa epitope
peptide primarily served as a control to identify that is was, in fact, this autoantibody which
was responsible for the pathophysiology observed. Because the AT1-AA derived from many
different patients consistently interacted with the same epitope present on the second
extracellular loop of the AT1 receptor, it suggests a common immunologic origin of these
autoantibodies. 7-aa was highly effective in reducing the actions of the injected AT1-AA. It can
therefore be inferred that they share a strong interaction and bind well to one another.
Unfortunately, it is unlikely that this short peptide would remain stable in the circulation of
humans or mice if it were not bound in complex with the autoantibody. Freely circulating
peptidases would likely destroy it rapidly. Should 7-aa be used in preclinical studies and
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potential clinical trials, the synthesis of stable derivatives will be necessary. Further
investigation is warranted to fully exploit the therapeutic potential suggested by the results of
these autoantibody-neutralization experiments. In a similar regard, the use of anti-idiotype
antibodies directed at different antigen-binding regions of AT1-AA could be employed
therapeutically. However, it must be recognized that AT1-AA stimulate the production of other
detrimental molecules (e.g. sFlt-1, TNF-α, sEng, PAI-1, tissue factor, endothelin-1, ROS,
NADPH oxidase), which can all contribute to the symptoms of PE. Blocking the autoantibody
at the time of symptom-onset may not be sufficient to immediately lead to their abatement
[149, 224]. Similar limitations would presumably apply to the potential use of plasmaphoresis,
a strategy successfully employed in other autoimmune diseases, such as multiple sclerosis,
which removes the harmful autoantibodies from circulation [341]. In the case of PE, once
symptoms have arisen, many of the aforementioned factors would already be greatly elevated,
and not be filtered from the blood during the process of plasmaphoresis. As they would remain
in circulation, these factors would continue to incite damage and provoke preeclamptic
features. Since the autoantibody likely appears several weeks prior to symptom development, it
will be necessary to generate a screening method to detect it as early as possible. In this way,
AT1-AA-mediated inductions of other factors may be blocked before they are fully elevated
and maximum therapeutic benefit could be achieved.

Autoimmune disease: a new classification of PE?
It would be remiss to avoid commenting on the fact that it is currently not the consensus
of the field at-large that PE as an autoimmune disease specific to pregnancy; despite the
growing body of work implicating the role of AT1-AA.
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Indeed, the as the in vitro and in vivo evidence mounts to support the case of AT1-AA in
the pathogenesis of PE, other human diseases have been linked to autoantibodies capable of
activating G-protein-coupled receptors. As previously mentioned, Graves' disease, is an
autoimmune condition wherein autoantibodies target thyroid cells and activate the thyroid
stimulating hormone receptor, resulting in excessive production and secretion of thyroid
hormones resulting in hyperthyroidism [201]. Some forms of hypoglycemia are associated with
autoantibodies which agonize the insulin receptor [342]. Patients with dilated cardiomyopathy
harbor autoantibodies directed against cardiac β1-adrenergic receptors, resulting in a positive
chronotropic effect in cultured cardiomyocytes [343]. Using a rat model, Jahns et al. provided
direct evidence for autoimmune-induced β1-adrenergic receptor activation as a cause of
idiopathic dilated cardiomyopathy [344]. This group later showed that patients who possess
these autoantibodies are at increased risk for future cardiovascular disease and mortality [345].
Autoantibodies which increase α1-adrenergic receptor activity are also associated with several
forms of hypertension [346, 347]. Finally, autoantibodies which activate the muscarinic M2
receptor are also found in some patients with idiopathic dilated cardiomyopathy [33]. Thus
agonistic autoantibodies which target and agonize G-protein-coupled receptors are commonly
observed in many human conditions and considered a pathogenic factor leading to symptom
development. AT1-AA, which agonizes the Gq-coupled AT1 receptor, may soon be recognized
in that category. The findings presented here raise the intriguing possibility that PE may be an
autoimmune disease associated with AT1-AA.
Whether one believes PE is an autoimmune disease or not, it cannot disputed that AT1AA are found in the serum of preeclamptic patients and that they potentially contribute to the
systemic symptoms. What initiates and perpetuates the generation of these autoantibodies are
still areas of speculation which require further investigation. We believe that in the near future
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PE will be considered a pregnancy-induced autoimmune condition, which could provide the
field of immunology insight into how other conditions of autoimmunity arise and flourish.

Significance

Preeclampsia is encountered in 7% of pregnancies, responsible for 15% of all preterm
births and 18% of all pregnancy-related maternal deaths in the US every year [29, 30, 178].
These are not merely statistics, but represent hundreds of thousands of families which are
affected by this devastating disorder of pregnancy and billions of dollars spent in PE-related
healthcare costs. Right now, delivery of the baby and placenta is our only option to “cure” PE.
These deliveries, often premature, pose considerable immediate risk to both mom and baby, not
to mention their increased risk for long-term health sequelae. Improvement upon the screening,
diagnosis and treatment of this disorder are clearly required and essential to advancing the care
not only in the US, but also in developing countries, where the prevalence of PE can be twice
as high and the rate of death several fold higher as compared to developed nations [31, 348].
The research presented here expands our understanding of PE and the role that AT1-AA
may play in the manifestation of the disorder. Any insight into the disease mechanism and the
identification of pathogenic players could improve upon the limited screening and therapeutic
strategies available in its clinical management. It was shown that this autoantibody can induce
preeclamptic-like symptoms in mice and that losartan, 7-aa and anti-TNF-α treatments can
specifically reduce them. These facts have significant therapeutic implications: specific
neutralization of the autoantibody in preeclamptic women could alleviate their symptoms.
Moreover, should we develop an improved method of identifying the autoantibody, physicians
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would be able to screen for AT1-AA early in pregnancy and then block autoantibody-mediated
AT1 receptor activation or downstream molecules’ actions. This blockade could forestall or
prevent preeclamptic symptom, thereby reducing the short- and long-term risks to preeclamptic
mothers and their unborn children.
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FUTURE DIRECTIONS

Though the recent work reported by Dr. Xia’s lab clearly establishes the
pathophysiologic role of AT1-AA in PE, there are still many mechanistic aspects to explore. In
the near future, this group will attempt to: establish a timeline of autoantibody generation in
pregnant women; determine the role of LIGHT, an emerging TNF-α superfamily member
which contributes to apoptosis and inflammation, in AT1-AA-mediated PE; and finally, to
elucidate the relationship between the autoantibody and syncytiotrophoblastic microparticles
(STBMs) and their role in preeclamptic symptom development.

Detection of AT1-AA in CPEP clinical trial samples
The two most common, and arguably the most important, questions asked to our group
and the other investigators studying AT1-AA are: (i) when does the autoantibody appear during
gestation, and (ii) does the generation of AT1-AA precede preeclamptic symptom development.
In order to answer these questions, one must have a collection of well-defined preeclamptic and
control serum samples which span the course of gestation. In recent months, we have acquired
just that. Based on our recent publication using the luciferase-based bioassay to detect AT1-AA
in pregnant women [34], we have begun what will surely be a fruitful collaboration with Dr.
Richard Levine of the NIH.
To answer these two important clinical questions, we will employ the luciferase-based
bioassay to detect AT1-AA in the serum samples collected for the large-scale, nationwide
Calcium for Preeclampsia Prevention (CPEP) Trial. These are the same valuable samples used
in two landmark publications which clearly established the relationship between sFlt-1 and
125

sEng levels and the onset of PE [37, 61]. Our hypothesis is that the detection of AT1-AA may
precede overt preeclamptic symptoms in these patient samples.
In total, we will obtain at least 3 serum samples from various time-points throughout the
pregnancies of: 120 normotensive women, 120 women who were normotensive and delivered
SGA infants, 120 women with gestational hypertension, 72 women with preterm PE and 120
women with term PE. First, we will use our sensitive bioassay to detect AT1-AA and correlate
its presence with onset of PE symptoms, in particular, the induction of the two anti-angiogenic
factors, sFlt-1 and sEng. Secondly, by establishing a timeline of autoantibody generation in this
large bank of well-characterized samples, we hope to generate a means to identify women at
risk for PE – a tool lacking in the clinical management of this disorder.

Preliminary data: AT1-AA-CPEP Pilot Study
Recently, we conducted a pilot study to determine if our assay was capable of detecting
the biologic activity of AT1-AA isolated from these samples. Dr. Levine and his team randomly
blinded us to 24 CPEP serum samples, and we ran them in our standard manner [34]. For each
sample, we completed 4 luciferase readings and the average value of was computed to calculate
a raw delta value and a fold-induction ratio for each sample by dividing the average value of
the background controls in each batch (Fig. 33).
Though we received 24 samples, upon completion of the pilot study, we were informed
that in fact there were only 12 patients in this pool, and that duplicates had been provided.
Repeated measure analysis for ANOVA was applied to evaluate the within treatment effect
(duplicate measurements for each patient) and between treatment effect (PE vs. NT). No
significant difference was detected between the two duplicates in either raw delta or ratio
values, P=0.3937. However, the PE group showed significantly higher deltas and ratios
126

compared to NT. Paired t-test and non-parametric Wilcoxon test were also used for additional
testing on within and between treatment effects. The results were consistent with the repeated
measure analysis.

Figure
33:
AT1-AA
bioactivity was successfully
detected in CPEP serum
samples. A total of 12
samples from the CPEP trial
were
randomized
and
measured in blinded duplicate
by
an
NFAT-luciferase
bioassay. Normotensive (NT),
n=6; Preeclampsia (PE), n=6.
There
is
a
significant
difference between NT and PE
groups (P<0.0015), but no
significant difference between
duplicates.

The consistency of the bioassay between duplicates and statistically significant
differences achieved between the two groups of interest in the AT1-AA-CPEP Pilot Study
results are highly encouraging. We are excited to proceed generating similar data in the near
future with the remaining ~950 samples. Determining a clear and early biomarker for PE may
provide a therapeutic window which could allow for the neutralization or removal of AT1-AA,
providing significant preventative measures to forestall the devastating symptoms of PE and
subsequent fetal IUGR.
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AT1-AA and syncytiotrophoblastic microparticles
One feature of preeclamptic women which has puzzled investigators is the presence of
increased syncytiotrophoblast microparticles (STBMs). STBMs are membrane-bound placental
cell fragments produced by apoptotic activity or by vesicle secretion [349, 350]. In normal
pregnancy, minimal STBMs are shed from the placenta into maternal circulation, in contrast to
PE, where there is excessive shedding and increased circulating STBMs [351]. The cause for
this excess shedding is undetermined. It may be due to the poor placental perfusion leading to
hypoxic injury and/or excessive trophoblast apoptosis characteristic of preeclamptic placentas
[352, 353]. Additionally, it is unknown what pathophysiology, if any, results secondary to these
circulating microparticles. Redman et al., believe that this STBM overload could be a stimulus
for the maternal inflammatory response and the systemic endothelial cell damage observed in
the disorder [354]. Others believe that since STBMs contain trophoblasts of fetal origin, which
could be interpreted by maternal immune cells as foreign, a maternal immune response may be
mounted [266]. Therefore, we will set out to answer a classic ‘chicken or the egg’ mystery, and
will determine if STBMs represent a rich source of antigenic stimulation for the mother,
resulting in the generation of AT1-AA and the maternal syndrome of PE; or if the autoantibody
precedes and is a driving force for the liberation of STBMs themselves.
In order to investigate the pathophysiologic consequences of STBMs, we must generate
them. This can be achieved using several techniques: HTR-8 cells, mouse and human villous
explants will be cultured under normoxic and hypoxic conditions as well as being treated with
the apoptotic-inducing agents TNF-α and rotenone [355, 356]. STBM production will be
quantified using flow cytometry using the trophoblastic marker, HLA-G, in a method similar to
Orozco, et al. [357]. Then, STBMs will be analyzed by western blot for the presence of the AT1
receptor, a possible antigenic source for AT1-AA generation. Furthermore, the cultured STBMs
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could be injected into pregnant mice which will be monitored for preeclamptic features and the
generation of the autoantibody. We expect that STBM production will be increased under
hypoxic conditions, and that TNF-α and rotenone will induce their production via increased
apoptosis. Pregnant mice injected with excess STBMs may demonstrate a preeclamptic-like
syndrome and if injected early enough, may also generate AT1-AA.
Alternative to the timeline studies are those characterizing the cell-surface receptor
profiles of STBMs throughout both uncomplicated and preeclamptic pregnancies. Appropriate
integrin subunit switching is essential for a healthy pregnancy as it enables trophoblasts to fully
infiltrate maternal decidual and endothelial linings [358, 359]. Cytotrophoblasts in the villous
express epithelial-like integrins (α6β4). As they migrate towards the decidual endothelium,
their integrins transform to a vascular-type (α1β3 or α5β3) [359]. This switching is aberrant in
PE and results in shallow trophoblast invasion and inadequate endothelial cell infiltration [360].
Notably, this type of integrin switching is mediated by AT1-receptor activation in other systems
[361]. We plan to isolate STBMs from these two pregnant groups using established methods
[351] and characterize their epithelial or endothelial-like cell surface markers using flow
cytometry analysis. Since STBMs take on the composition of the cells from which they
originate, we expect there to be a defined expression pattern of cell surface markers in PE
versus NT STBMs (epithelial versus vascular) [169].
Overall, a woman’s STBM marker profile could provide a novel screening tool as
certain cell surface markers could indicate a risk factor for PE (e.g. integrin α6β4).
Additionally, if STBMs prove to induce AT1-AA production, these women would be at even
higher risk for developing a hypertensive pregnancy. Any additional tools, such as an STBM
cell surface marker profile, used for the screening of PE will be beneficial, as they allow for
closer monitoring of high risk women and create a window for early intervention.
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See the LIGHT and its role in PE
LIGHT [homologous to Lymphotoxin, exhibits Inducible expression, competes with
HSV Glycoprotein D for Herpes virus entry mediator (HVEM), a receptor expressed by T
lymphocytes] is a recently identified (and rather lengthily-named) type II transmembrane
glycoprotein of the TNF ligand superfamily [362]. It has been recognized as a major
contributor to the inflammation and increased apoptosis observed in several human diseases.
By binding to HVEM, LIGHT co-stimulates T cells to accelerate their proliferation and
cytokine production. In several tumor cell lines, LIGHT induces apoptosis and recent studies
have suggested a potential role of LIGHT in inflammatory diseases including: atherosclerosis,
arthritis, IgA nephropathy, hepatitis and inflammatory bowel disease [363-366]. Soluble
LIGHT has been detected in these many in vitro system studies, however its presence and
function in inflammatory diseases have not been explored in vivo. Moreover, the role of this
inflammatory mediator has not been investigated at all in the field of PE. After reviewing the
literature by which LIGHT produces pathology in other disorders, we decided that it may be a
potential pathogenic player in PE, and will further investigate this novel target.
Before determining if the autoantibody and LIGHT share a pathophysiologic
relationship, we must first establish if LIGHT is increased in the circulation of preeclamptic
women. For a pilot study, we collected plasma samples from both PE and NT pregnant women.
Once our patient samples were acquired, we ran an ELISA for LIGHT (R&D Systems) to
determine its level in circulation. The data for this initial study is provided here (Fig. 34).
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Preliminary data: Circulating LIGHT is increased in preeclamptic women
The circulating LIGHT measured in patient
plasma indicates preeclamptic women have a
significantly

increased

level

over

their

NT

counterparts (Fig. 34). None of the NT patient
samples had markedly increased serum levels of
LIGHT. Of the PE patient samples, 9 of 34, or ~26%
showed a significant increase in the circulating level
of the glycoprotein. The means for NT and PE
plasma LIGHT levels were 0.99 and 26.45 pg/ml
respectively, P=0.0066. Though not every PE patient
demonstrated increased LIGHT, a value of ~26% of
patients with increased levels is considered clinically
worthwhile to pursue. This percentage could also be
explained if the ELISA is not an adequately sensitive

Figure 34: Circulating LIGHT is elevated in
preeclamptic women. ELISA measurement
of circulating LIGHT in preeclamptic (PE;
n=34) and normotensive (NT; n=33) pregnant
women reveals a significant increase in PE
patients. Dotted line; lowest detectable level of
assay.

detection method for this molecule. Certainly, further
confirmation of elevated LIGHT in preeclamptic
women is necessary. Therefore, the next step will be
to collect the placentas from affected women with

PE and measure both the transcript and protein level of LIGHT (by RT-PCR and western,
respectively). Then, should the levels be increased and we are satisfied that this inflammatory
agent is consistently increased in PE, we will move forward into in vitro and in vivo studies.
We will culture human villous explants with ANG II or PE-IgG, and after a period of
incubation, measure the amount of LIGHT liberated into the supernatant by the explants. At
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this moment, there is no literature which delineates the mechanisms by which LIGHT is
increased. Since many other TNF-related inflammatory molecules are increased by AT1
receptor stimulation [206, 257, 259, 367], it is plausible that LIGHT may also be. Should this
inflammatory mediator be increased by PE-IgG not by NT-IgG, then perhaps AT1-AA induces
LIGHT, which may play a causative role in the manifestation of PE. We could then pursue in
vivo studies by injecting recombinant LIGHT into pregnant mice and then monitor them for
disease symptoms, such as hypertension and renal dysfunction. We could also ascertain if AT1AA injected mice generate excess LIGHT and if so, whether co-injection of the autoantibody
and losartan or 7-aa reduces this value. All of these exciting projects will help establish LIGHT
as a novel inflammatory mediator in the pathogenesis of PE, and may potentially create a
therapeutic opportunity in the years to come.

Overall goals of future work
The future work presented here seeks to further characterize AT1-AA in the
pathophysiology of PE. Currently, this prevalent disorder is not considered an autoimmune
process; however, the growing body of work implicating AT1-AA in its pathogenesis could
lead to a paradigm shift in its screening, diagnosis and treatment. The results from the CPEP
study could yield more defined dates for early screening of the autoantibody and STBM
profiles prior to onset of preeclamptic symptoms. This could improve upon the limited clinical
management available. In addition, if autoantibody-induced features could be specifically
blocked by a drug or peptide targeting a novel molecule, such as LIGHT, perhaps the
progression of this disease could be abated and the morbidity and mortality associated with this
hypertensive disorder could be reduced.
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